Download Free Medical Biopharmaceuticals in Perspective PowerPoint Presentation

Biopharmaceuticals in Perspective PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This report by Pharmaceutical Research and Manufacturers of America (PhRMA) provides facts and figures about prescription medicines and their role in the healthcare system. Topics in this report on biopharmaceuticals includes medicines’ effect on health and quality of life, the drug discovery and development process, healthcare spending and costs, the challenges of filling treatment gaps and improving the use of prescribed therapies, the contributions of the biopharmaceutical sector, and costs and access in other developed countries.

Tags : pharma, pharmaceutical, pharmaceutical industry, drugs, medicine, Biopharmaceuticals, Pharmaceutical Research, drug discovery, drug development

Published on : Jul 02, 2020 | Views : 1760 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

CHART PACK BIOPHARMACEUTICALS IN PERSPECTIVE SUMMER 2019
Slide 2-

Dr. Ryan Ryan is a senior research scientist who works to discover potential treatments for autoimmune conditions like lupus. Ryan believes nothing is possible without innovation, which spurs his drive and passion to keep moving forward despite the numerous setbacks researchers in his field commonly face. Mitra Mitra is a school counselor living with an autoimmune disease she fights daily. Knowing that an army of researchers is working to develop the next treatment to improve her own and others’ lives serves as a source of optimism for Mitra and helps her maintain the resilience needed to face the challenges caused by her disease. RESEARCHERS MAKING AN IMPACT
Slide 3-

iii TABLE OF CONTENTS Cover photo: Dr. Ryan Moslin, Bristol-Myers Squibb researcher, and Mitra, autoimmune disease survivor Introduction 1 1 Advances in Treatment 3 2 Research and Development 25 3 Market Dynamics 53 4 Cost Sharing Trends 79 5 Spending on Medicines 97 6 Outcomes and Savings 119 7 Economic Impact 133 8 International Costs and Access 155 3
Slide 4-

Photo placeholder 4
Slide 5-

INTRODUCTION This chart pack provides facts and figures about prescription medicines and their role in the health care system. Topics include medicines’ impact on health and quality of life, the drug discovery and development process, health care spending and costs, the challenges of addressing treatment gaps and improving the use of prescribed therapies, the contributions of the biopharmaceutical sector, and costs and access in other developed countries. Data and information in this publication were drawn from a wide range of sources, including government agency reports, peer-reviewed journals, and the Pharmaceutical Research and Manufacturers of America’s (PhRMA’s) own research and analysis. PhRMA hopes this publication provides useful context for discussions regarding the role of medicines and the US economy. 1
Slide 6-

2
Slide 7-

3 ADVANCES IN TREATMENT Medicines’ Impact on Health and Quality of Life Prescription medicines have yielded important advances, helping patients live longer and healthier lives. Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer, and hepatitis C, resulting in decreased death rates, improved health outcomes, and better quality of life for patients. Today, new drugs are targeting the underlying causes of disease in ways never seen before, and diseases previously regarded as deadly are now manageable and even curable. In this new era of medicine, breakthrough science and personalized therapies are revolutionizing the way we treat patients with a broad range of chronic and rare conditions. Looking forward, continued advances in biopharmaceutical innovation will be critical in addressing unmet needs, improving public health, and solving future health care challenges. 1 3
Slide 8-

Increases in US Life Expectancy Innovative medicines have played an integral role in improving life expectancy over the last century.1 US Life Expectancy, 1950-20172* *Life expectancies before 1997 and those in and after 1997 were calculated using a slightly different methodology. 60 65 70 75 80 85 2010 2000 1990 1980 1970 1960 1950 77.4 78.8 79.3 81.0 81.1 Life Expectancy at Birth (in Years) 71.1 73.1 74.7 70 71.8 74.1 76.2 76.1 65.6 66.6 67.1 2020 2017 Women Men 4 1 Advances in Treatment Sources: CDC1,2
Slide 9-

A Decade of Advances 2009 First treatment for peripheral T-cell lymphoma First new drug for gout in 40 years 2017 2013 2015 2011 2 new personalized medicines to treat the most dangerous forms of skin cancer New oral treatment for multiple sclerosis 2 new drugs for difﬁcult-to-treat forms of high cholesterol New cystic ﬁbrosis drug for patients with a genetic mutation that is the most common cause of the disease First lupus drug in 50 years 2 new personalized medicines First gene therapies approved First drug to treat primary progressive multiple sclerosis 16 new drugs to treat cancer 2008 New type of treatment for Crohn’s disease First drug for symptoms of Huntington’s disease 2010 2 new multiple sclerosis drugs First therapeutic cancer vaccine 2012 2014 2016 New drug class to treat HIV in patients who failed other therapies First new treatment in 10 years to alleviate pain caused by endometriosis 3 new drugs to prevent migraines 2018 spinal muscular atrophy New personalized therapy for chronic lymphocytic leukemia First drug to treat all 6 forms of hepatitis C First drug to target root cause of cystic ﬁbrosis First drug to treat Cushing’s disease Oral treatments • First drug to treat for hepatitis C provide cure rates of more than 90% 17 new drugs to treat patients with rare diseases 5 1 Advances in Treatment Source: FDA3
Slide 10-

Multiple Sclerosis (MS) Advances in recent years, including convenient oral medicines and the first-ever treatment for progressive MS, offer patients greater opportunity to better manage MS and slow disease progression.4 Rheumatoid Arthritis (RA) Therapeutic advances have transformed the RA treatment paradigm, shifting from a focus on managing symptoms to aiming for slowed disease progression and even disease remission.8 Cancer New therapies have contributed to a 27% decline in cancer death rates since the 1990s.6 The chance a cancer patient will live 5 years or more has increased 41% across all cancers since 1975.7 Hepatitis C Recent therapeutic advances can cure the disease and help patients avoid serious disease complications—including cirrhosis, advanced liver disease, liver cancer, and death.5 Medicines Are Transforming the Treatment of Many Diseases 6 1 Advances in Treatment Sources: PhRMA4,5; Siegel RL et al.6; ACS7; Boston Healthcare Associates8
Slide 11-

Medicines Are Transforming Treatment of Many Rare Diseases Collectively, rare diseases affect 30 million Americans. Treatments are available for only 5% of rare diseases, but recent advances are providing important new options to many patients for the first time.9 Fabry Disease10 Fabry disease is a genetic disorder that can cause fat buildup in blood vessels, nerves, and other organs and slowly progress to kidney disease, abnormal heart rhythm, stroke, and early death. The first treatment for adults was approved in 2018 and works by increasing the activity of a deficient enzyme. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)13 BPDCN is an aggressive blood cancer affecting multiple organs, including the lymph nodes and skin. The first treatment specifically for BPDCN was approved in 2018 for adults and children. Prior to this treatment, intensive chemotherapy and bone marrow transplant had been the standard of care. Hereditary Transthyretin- Mediated Amyloidosis (hATTR)12 hATTR interferes with the normal functioning of nerves, heart, and other organs and can lead to loss of sensation, pain, or immobility in the limbs. The first treatment for this often fatal genetic disease was approved in 2018 and targets the root cause by interfering with abnormal RNA protein production. Primary Hemophagocytic Lymphohistiocytosis (HLH)11 Primary HLH is an inherited and life- threatening immune disorder typically affecting children. The disorder causes damage to various organs, including the liver, brain, and bone marrow. The first treatment specifically for HLH was approved in 2018 for adults and children. 7 1 Advances in Treatment Sources: Global Genes9; FDA10-13
Slide 12-

THEN: Treatments for rheumatoid arthritis were generally effective at reducing joint inflammation but were limited to treating the symptoms of the disease, allowing for a steady, rapid progression from disease onset to disability. NOW: Biologic disease-modifying antirheumatic drugs target the underlying sources of inflammation, which improves physical functioning and prevents irreversible joint damage, making disease remission possible. Rheumatoid Arthritis: Medicines Are Transforming the Lives of Patients 8 1 Advances in Treatment Source: Boston Healthcare Associates14
Slide 13-

AIDS Mortality in the United States 0 5 10 15 The number of AIDS deaths in the US decreased dramatically following the introduction of highly active antiretro- viral therapy (HAART) combinations in 1996. As a result of HAART and all the important medical innovations that followed, it is estimated that more than 862,000 premature deaths have been avoided in the United States alone.15 Annual Number of AIDS Deaths in the United States16,17 20 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Deaths per 100,000 Population 9 1 Advances in Treatment Sources: Truven Health Analytics15; CDC16,17
Slide 14-

HIV/AIDS: Treatment Advances Build Over Time Dramatic declines in death rates did not occur with one single breakthrough but rather through a series of advances providing important treatment options for patients over time.18,19 *AZT: Azidothymidine 2001 1991 2006 1995 1984 2011 2017 First nucleotide analog approved AZT labeling expanded for dosing, earlier use, and pediatric use 1987 1994 1996 2003 2007 First treatment introduced: AZT* (a nucleoside analog reverse- transcriptase inhibitor) Rates of transmission from mother to infant dropped to less than 2% First one- pill-a-day treatment approved to reduce the risk of transmis- sion from mother to infant First protease inhibitors approved HIV identiﬁed as the cause of AIDS fusion inhibitors approved HAART combinations introduced AZT found • First • First C-C chemokine receptor type 5 agonist approved HHS recommended earlier initiation of treatment to control immunologic response 2012 First approval of a medicine for preexposure prophylaxis (PrEP) 1981 AIDS ﬁrst reported HIV/AIDS death rate PrEP AZT in the US dropped 88% since the introduction of HAART 88% 10 1 Advances in Treatment Sources: Boston Healthcare Associates18; CDC19,20
Slide 15-

I think some of the treatments that we have developed over the last half century or so are really starting to pay off and, honestly, [it] seems limitless as to what may pay off in the future.” — William Nelson, MD, PhD, Director, Sidney Kimmel Comprehensive Cancer Center24 Cancers: Decline in Death Rates Since peaking in the 1990s, cancer death rates have declined 27%.21 Approximately 73% of survival gains in cancer are attributable to new treatments, including medicines.22 1991-2000 2001-2010 2011-2016 Total Decline 27% 7.6% 12.5% 7.6% Percent Change by Decade in US Death Rates From Cancer21,23 11 1 Advances in Treatment Sources: Siegel RL et al.21; Seabury SA et al.22; NCI23; Dunellari A24
Slide 16-

After Introduction of Imatinib Before Introduction of Imatinib 31% 89% Chronic Leukemia: Increased Survival Rates When the first-in-class drug imatinib was approved in 2001 to treat chronic myeloid leukemia (CML), the transformative impact of this new class of medicines had not been completely realized.25 After initial approval, continued research revealed that imatinib had a greater impact when initiated earlier in the progression of the disease. Further research revealed that imatinib was effective in combating other types of cancer. Additional drugs in this class have since been approved that target mutated forms of CML in patients who have become resistant or intolerant to imatinib.26 Today, survival rates have improved dramatically, and CML patients are living close to normal life spans.27 5-Year Survival Rates for CML Patients28,29 12 1 Advances in Treatment Sources: Boston Healthcare Associates25; PhRMA26; Gambacorti-Passerini C et al.27; ACS28; Druker BJ et al.29
Slide 17-

300 200 100 0 400 500 600 700 2017 2018 Rare diseases are those that affect 200,000 or fewer people in the United States.30 Number of Drug Approvals for Rare Diseases31* 800 2015 2013 2011 2009 2007 2005 2003 2001 1999 1997 1995 1993 1991 1989 1987 1985 1983 Cumulative Prior Orphan Drug Approvals New Orphan Drug Approvals *Drug approvals for rare diseases include initial approvals of new medicines and subsequent approvals of existing medicines. Rare Diseases: Drug Approvals for Rare Diseases Have Increased of the Orphan Drug Act in 1983, CONTINUED INNOVATION Although more than 750 orphan drugs have been approved since the passage is still very much needed.30 13 1 Advances in Treatment Sources: NIH30; FDA31
Slide 18-

50 0 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016 100 150 200 250 300 350 400 389 379 365 353 Age-Adjusted Death Rates per 100,000 322 306 300 288 272 258 245 222 206 192 179 171 167 166 Cardiovascular Disease: Declining Rates of Death Tremendous strides have been made in reducing cardiovascular disease morbidity and mortality, thanks in part to new medicines. US Death Rates Due to Diseases of the Heart* 450 *Age-adjusted death rates based on year 2000 US standard population. 1980-1998 causes of death are classified by the International Classification of Diseases, Ninth Revision (ICD-9). Beginning in 1999, causes of death have been classified by the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Sources: CDC32,33 Since 2000 alone, the death rate from HEART DISEASE has declined by 36%. 14 1 Advances in Treatment
Slide 19-

Medicines Are Improving Patients’ Quality of Life *HIV, rheumatoid arthritis, leukemias, non-Hodgkin’s lymphoma, multiple sclerosis, and lupus **Chart reflects unweighted estimates reported in study. 765,500 fewer patients 408,000 fewer patients 306,000 fewer patients 289,000 fewer patients Relative to medical technology available a decade ago, new treatments for complex chronic conditions are better tolerated, more efficacious, and more convenient, thereby improving not only life expectancy, but quality of life for patients. 10-Year Decline in Number of Patients With Complex Chronic Conditions* Experiencing Quality-of-Life Impairment** Functional Physical Social Cognitive -9% -5% -4% -3% 15 1 Advances in Treatment Source: Brien MJ et al.34
Slide 20-

Hepatitis C: Advances Driving Down Prevalence of Disease 2010 2012 2014 2016 2018 2020 2022 2024 *Model takes into account launch of DAAs, change in HCV screening policies, and implementation of the Affordable Care Act. 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 1st Generation DAAs (Protease Inhibitors) 2026 2028 2030 Sources: Chhatwal J et al.35; PhRMA36; FDA37 63-80% 2nd Generation DAAs (Polymerase Inhibitors) 3rd Generation DAAs (Combination Antivirals) 84-90% 93-100% The introduction of direct-acting antivirals (DAAs) and subsequent improvements in cure rates revolutionized the treatment of hepatitis C (HCV), significantly driving down prevalence of disease. Decreasing Number of HCV-Infected Patients, by Insurance Type, US 2010-203035* Cure Rates36,37 Cumulative Prevalence Other Public Medicaid Medicare Private Uninsured 16 1 Advances in Treatment
Slide 21-

Hepatitis C Medicines Produce Savings in Medicaid By 2019, total cumulative costs of HCV treatment since the introduction of highly effective interferon-free DAAs are expected to be fully offset by total cumulative health care costs associated with avoided costly disease complications in Medicaid. By 2020, these total cumulative savings are estimated to reach $12 billion. HCV DAA Therapy: Short-term Costs and Long-term Savings in Medicaid, 2013-2022 (in Millions) $5,000 $4,000 $3,000 $2,000 $1,000 $0 -$1,000 -$2,000 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Interferon- free DAAs introduced 17 1 Advances in Treatment Source: Roebuck MC et al.38
Slide 22-

*Assumes research advances that delay the average age of onset of Alzheimer’s disease by 5 years beginning in 2025. **Projected savings to Medicare and Medicaid assume research breakthroughs that slow the progression of Alzheimer’s disease. This would dramatically reduce spending for comorbid conditions and expensive nursing home care. Unmet Need: Future Impact of New Treatments for Alzheimer’s Disease The development of a new treatment that delays the onset of Alzheimer’s disease could reduce Medicare and Medicaid spending on patients by $218 billion annually by 2050.* Projected Annual Medicare and Medicaid Spending With and Without New Treatment Advances (in Billions)** $182 $262 $377 $547 $182 $310 $529 $765 2020 2030 2040 2050 Current Trajectory Projected With Delayed Onset Due to Treatment Advances 18 1 Advances in Treatment Source: Alzheimer’s Association39
Slide 23-

Notes and Sources Centers for Disease Control and Prevention (CDC). Ten great public health achievements—United States, 1900-1999. https://www.cdc.gov /mmwr/preview/mmwrhtml/00056796.htm. Accessed May 2017. Murphy SL, Xu JQ, Kochanek KD, et al.; Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Mortality in the United States, 2017. NCHS Data Brief 328. https://www.cdc.gov/nchs/data/databriefs/db328-h.pdf. Published November 2018. Accessed April 2019. Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Advancing health through innovation: 2018 new drug therapy approvals. https://www.fda.gov/media/120357/download. Published January 2019. Accessed April 2019. Pharmaceutical Research and Manufacturers of America (PhRMA). Multiple sclerosis: expanded treatment options improve outcomes for a disabling chronic condition. In: A Decade of Innovation in Chronic Diseases: 2006-2016, 14-16. http://phrma-docs.phrma.org/sites/default/files /pdf/decade-of-innovation-chronic-disease.pdf. Published February 2016. Accessed April 2018. Pharmaceutical Research and Manufacturers of America (PhRMA). Hepatitis C: breakthroughs revolutionize treatment for patients. In: A Decade of Innovation in Chronic Diseases: 2006-2016, 25-28. http://phrma-docs.phrma.org/sites/default/files/pdf/decade-of-innovation-chronic -disease.pdf. Published February 2016. Accessed April 2018. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. https://onlinelibrary.wiley.com/doi/full/10.3322/caac .21551. Accessed April 2019. American Cancer Society (ACS). Cancer facts & figures 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and -statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Published 2018. Accessed April 2018. Augustyn C, Walker B, Goss TF; Boston Healthcare Associates. Recognizing the value of innovation in the treatment of rheumatoid arthritis. http://www.phrma.org/sites/default/files/pdf/BHARAWhitepaperMarch2013.pdf. Published March 2013. Accessed April 2018. Global Genes. RARE facts. https://globalgenes.org/rare-facts. Accessed May 2019. Food and Drug Administration (FDA). FDA approves new treatment for a rare genetic disorder, Fabry disease. https://www.fda.gov/news-events /press-announcements/fda-approves-new-treatment-rare-genetic-disorder-fabry-disease. Published August 10, 2018. Accessed April 2019. Food and Drug Administration (FDA). FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-specifically-patients-rare-and-life-threatening -type-immune-disease. Published November 20, 2018. Accessed April 2019. 19 1 Advances in Treatment
Slide 24-

Food and Drug Administration (FDA). FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease. https://www.fda.gov /news-events/press-announcements/fda-approves-first-its-kind-targeted-rna-based-therapy-treat-rare-disease. Published August 10, 2018. Accessed April 2019. Food and Drug Administration (FDA). FDA approves first treatment for rare blood disease. https://www.fda.gov/news-events/press -announcements/fda-approves-first-treatment-rare-blood-disease-0. Published December 21, 2018. Accessed May 2019. Augustyn C, Walker B, Goss TF; Boston Healthcare Associates. Recognizing the value of innovation in the treatment of rheumatoid arthritis. http://www.phrma.org/sites/default/files/pdf/BHARAWhitepaperMarch2013.pdf. Published March 2013. Accessed May 2017. Lacey MJ, Hanna GJ, Miller JD, et al.; Truven Health Analytics. Impact of pharmaceutical innovation in HIV/AIDS treatment during the highly active antiretroviral therapy (HAART) era in the US, 1987-2010: an epidemiologic and cost-impact modeling case study. http://truvenhealth.com /Portals/0/Assets/Life-Sciences/White-Papers/pharma-innovation-hiv-aids-treatment.pdf. Published December 2014. Accessed March 2018. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Health, United States, 2016: with chartbook on long-term trends in health. https://www.cdc.gov/nchs/data/hus/hus16.pdf. Published 2017. Accessed June 2018. Xu JQ, Murphy SL, Kochanek KD, et al.; Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, National Vital Statistics System. Deaths: final data for 2016. Natl Vital Stat Rep. 2018;67(5):1-76. https://www.cdc.gov/nchs/data/nvsr/nvsr67/nvsr67_05.pdf. Accessed April 2019. Augustyn C, Walker B, Goss TF; Boston Healthcare Associates. Recognizing the value of innovation in the treatment of rheumatoid arthritis. http://www.phrma.org/sites/default/files/pdf/BHARAWhitepaperMarch2013.pdf. Published March 2013. Accessed May 2017. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Health, United States, 2016: with chartbook on long-term trends in health. https://www.cdc.gov/nchs/data/hus/hus16.pdf. Published 2017. Accessed June 2018. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics. AIDS and HIV: mortality. https://www.cdc.gov/nchs /fastats/aids-hiv.htm. Accessed May 2019. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21551. Accessed May 2019. Seabury SA, Goldman DP, Gupta CN, et al. Quantifying gains in the war on cancer due to improved treatment and earlier detection. Forum Health Econ Policy. 2015;19(1):141-156. Notes and Sources 20 1 Advances in Treatment
Slide 25-

National Cancer Institute (NCI), Surveillance, Epidemiology, and End Results Program. Cancer stats facts: Cancer of any site: number of new cases and deaths per 100,000 people (all races, males and females), age-adjusted. https://seer.cancer.gov/statfacts/html/all.html. Accessed May 2019. Dunellari A. Researchers optimistic about future of cancer treatment. VOA News. https://www.voanews.com/science-health/researchers -optimistic-about-future-cancer-treatment. Published January 13, 2016. Accessed May 2017. Goss TF, Picard EH, Tarab A; Boston Healthcare Associates. Recognizing value in oncology innovation. http://www.phrma.org/sites/default/files /flash/phrma_innovation_oncology.pdf. Published June 2012. Accessed May 2017. Pharmaceutical Research and Manufacturers of America (PhRMA). A decade of innovation in rare diseases: 2005-2015. http://phrma-docs .phrma.org/sites/default/files/pdf/PhRMA-Decade-of-Innovation-Rare-Diseases.pdf. Published 2015. Accessed May 2017. Gambacorti-Passerini C, Antolini L, Mahon F-X, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553-561. American Cancer Society (ACS). Cancer facts & figures 2012. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and -statistics/annual-cancer-facts-and-figures/2012/cancer-facts-and-figures-2012.pdf. Published 2012. Accessed May 2019. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. National Institutes of Health (NIH), National Center for Advancing Translational Sciences. FAQs about rare diseases. https://rarediseases.info .nih.gov/diseases/pages/31/faqs-about-rare-diseases. Last updated November 30, 2017. Accessed April 2019. Food and Drug Administration (FDA). Search orphan drug designations and approvals. http://www.accessdata.fda.gov/scripts/opdlisting/oopd /index.cfm. Accessed April 2019. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, National Vital Statistics System. Age-adjusted death rates for 72 selected causes by race and sex using year 2000 standard population: United States, 1979-98. http://www.cdc.gov/nchs/data /mortab/aadr7998s.pdf. Accessed May 2017. Xu JQ, Murphy SL, Kochanek KD, et al.; Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, National Vital Statistics System. Deaths: final data for 2016. Natl Vital Stat Rep. 2018;67(5):1-76. https://www.cdc.gov/nchs/data/nvsr/nvsr67/nvsr67_05.pdf. Accessed April 2019. Brien MJ, Carnow W, Dowdy MC, et al. Quantifying improvements in life quality of individuals with complex chronic medical conditions over the past decade. http://phrma-docs.phrma.org/files/dmfile/Study---Quality-of-Life-Improvements-Over-the-Past-Decade---March-2016.pdf. Published March 12, 2016. Accessed May 2017. Notes and Sources 21 1 Advances in Treatment
Slide 26-

Chhatwal J, Wang X, Ayer T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016;64(5):1442-1450. doi:10.1002/hep.28571 Pharmaceutical Research and Manufacturers of America (PhRMA). A decade of innovation in chronic diseases: 2006-2016. http://phrma.org /sites/default/files/pdf/decade-of-innovation-chronic-disease.pdf. Published February 2016. Accessed May 2018. Food and Drug Administration (FDA). Drugs@FDA: FDA approved drug products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed May 2018. Roebuck MC, Liberman JN. Burden of Illness of chronic hepatitis c and impact of direct-acting antiviral use on healthcare costs in Medicaid. Am J Manag Care. In press. Alzheimer’s Association. Changing the trajectory of Alzheimer’s disease: how a treatment by 2025 saves lives and dollars. https://www.alz.org /media/Documents/changing-the-trajectory-r.pdf. Published 2015. Accessed May 2017. Notes and Sources 22 1 Advances in Treatment
Slide 27-

Photo placeholder 23
Slide 28-

Photo placeholder 24
Slide 29-

25 RESEARCH AND DEVELOPMENT The Process of Drug Discovery and Development The rapid pace of scientific advances is bringing tremendous hope to patients. The pipeline for new medicines has never been more promising, with more than 8,000 medicines in development around the world. Over the past decade, PhRMA member companies have invested more than half a trillion dollars in biopharmaceutical research and development (R&D), accounting for the majority of private biopharmaceutical R&D spending. Development of new medicines is a long and rigorous process, with many setbacks along the way. As scientific complexities create new challenges in R&D, biopharmaceutical companies are working to create efficiencies and enter new collaborations across the research ecosystem. 2 25
Slide 30-

About 8,000 Medicines in Development Globally1 Biopharmaceutical researchers are pursuing many innovative scientific approaches that are driving therapeutic advances. 26 2 Research and Development Source: Adis R&D Insight Database1
Slide 31-

*Defined as single products that are counted only once regardless of the number of indications pursued About 4,500 Medicines in Development in the United States Biopharmaceutical researchers are working on new medicines* for many diseases, including: HIV 52 SKIN DISEASES 328 RARE DISEASES 566 CANCERS 1,120 ASTHMA & ALLERGY 130 MENTAL DISORDERS 140 NEUROLOGICAL DISORDERS 537 HEART DISEASE & STROKE 200 27 2 Research and Development Source: Adis R&D Insight Database2
Slide 32-

Potential First-in-Class Medicines in the Pipeline An average of 74% of drugs in the clinical pipeline are potential first-in-class medicines. Percentage of Products in Clinical Development and Regulatory Review That Are Potentially First-in-Class, Selected Therapeutic Areas, 2016 0% 20% 40% 60% 80% 100% Diabetes Cardiovascular Neurology Psychiatry Cancer Alzheimer's Disease 86% 79% 74% 73% 75% 73% 28 2 Research and Development Source: Analysis Group3
Slide 33-

Harnessing Innovation in Rare Diseases Since the passage of the Orphan Drug Act in 1983, we have seen tremendous advances in treatments for rare diseases,* with more than 770 orphan drug approvals (compared with fewer than 10 in the decade before passage).4 8,000 rare diseases known today5 There are Rare diseases affect 30 MILLION AMERICANS 85%-90% of rare diseases are serious or life-threatening More than 560 MEDICINES are in development for RARE DISEASES Approved treatments are available for ONLY 5% of all rare diseases *Rare diseases are defined as conditions for which there are fewer than 200,000 patients diagnosed in the United States. 29 2 Research and Development Sources: FDA4; Danese E et al.5; PhRMA6
Slide 34-

Cell and Gene Therapies Offer to Transform the Treatment of Disease An exciting field of medicine is emerging, offering the possibility of treating and even curing disease by directly altering genes and cells. At a basic level, these therapies entail genetic manipulation of cells either inside or outside the body so that cellular function is permanently changed within the body. These medicines are revolutionizing the way disease is treated, often offering profound and durable responses after a single dose or administration. Across multiple fields of science, we stand at an inflection point in medicine—where new technology is creating foundational opportunities to treat and cure disease in ways that weren’t possible just a short time ago…. Over the next several years, we’ll see this approach become a mainstay of treating, and probably curing, a lot of our most devastating and intractable illness.” — Scott Gottlieb, MD7 Commissioner, US Food and Drug Administration 5 diseases currently treated with cell and gene therapy 100+ diseases being explored for potential treatment with cell and gene therapies 289 cell and gene therapies in development 30 2 Research and Development Sources: FDA7; PhRMA8
Slide 35-

The Potential for Digital Health Advances to Enhance Drug Development and Patient Care Technological advances can increase access to clinical trials, enable efficient information exchange, speed drug development and delivery of new treatments, enhance clinical decision making, and engage patients. Patient Virtual Care Regulatory Process Improvements Data Solutions and Advanced Analytics Digital-based care delivery and digital therapeutics have the potential to reduce burden on patients, clinicians, and investigators. Continuous monitoring provides the ability to predict and detect health conditions. Artiﬁcial intelligence and machine learning have the potential to improve analysis, modeling, and evaluation. Patient Engagement and Support Digital technologies allow increased patient connectivity and empowerment. 31 2 Research and Development Source: Adapted from Avalere Health9
Slide 36-

Biopharmaceutical Companies Are Committed to Advancing Personalized Medicine In recent years, we have seen remarkable advances in targeted therapy, and the R&D pipeline has never been more promising. MORE THAN 42% 10 42%11 of new medicines IN THE PIPELINE have the potential to be of new medicines approved by the FDA in 2018 were PERSONALIZED MEDICINES 32 2 Research and Development Sources: Personalized Medicine Coalition10; Tufts CSDD11
Slide 37-

The R&D Process for New Drugs Is Lengthy and Costly, With High Risk of Failure From drug discovery through FDA approval, developing a new medicine takes, on average, 10 to 15 years and costs $2.6 billion.* Less than 12% of the candidate medicines that make it into Phase I clinical trials are approved by the FDA. PHASE I PHASE II PHASE III PHASE IV IND SUBMITTED NDA/BLA SUBMITTED FDA APPROVAL NUMBER OF VOLUNTEERS POTENTIAL NEW MEDICINES BASIC RESEARCH CLINICAL TRIALS FDA REVIEW POST-APPROVAL RESEARCH & MONITORING DRUG PRE- DISCOVERY CLINICAL 1 FDA- APPROVED MEDICINE TENS HUNDREDS THOUSANDS Key: IND=Investigational New Drug Application, NDA=New Drug Application, BLA=Biologics License Application *The average R&D cost required to bring a new FDA-approved medicine to patients is estimated to be $2.6 billion over the past decade (in 2013 dollars), including the cost of the many potential medicines that do not make it through to FDA approval. Sources: PhRMA adaptation of DiMasi JA et al.12; Tufts CSDD13; FDA14 33 2 Research and Development
Slide 38-

The Private Sector Leads the Translation of Basic Research Findings Into New Medicines 0% 20% 40% 60% 80% Manufacturing Development Discovery Percentage Contribution of R&D Milestones Achieved by Private and Public Sectors 100% Public Private 34 2 Research and Development Source: Chakravarthy R et al.15
Slide 39-

Biopharmaceutical Industry Does the Majority of Research to Translate Basic Science Into New Medicines Applied Research Basic Research Basic Research While basic science is often initiated in government and academia, it is biopharmaceutical firms that provide the necessary expertise and experience needed to develop new medicines.16 2017 Biopharmaceutical Industry R&D Investment: $97 Billion17 Applied Research 2017 NIH Research Spending: $32.6 Billion17 In addition to basic research and biopharmaceutical- related research, NIH supports applied research on medical devices, diagnostics, prevention, and other areas.18 35 2 Research and Development Sources: Chakravarthy R et al.16; Research!America17; NIH18
Slide 40-

Innovative Biopharmaceutical Companies Sit at the Heart of a Dynamic R&D Ecosystem in the United States The vibrant US biomedical R&D ecosystem is critical in bringing new medicines to patients and maintaining US leadership in biopharmaceutical R&D. FDA Clinical Trial Sites Clinical Research Organizations NIH Pharmacists & Providers New Medicines to Patients Biopharma Research Companies Nonproﬁts Venture Capital Patent & Trademark Ofﬁce Startups Academic Research Institutions 36 2 Research and Development
Slide 41-

Technology Transfer Between Universities and Industry Has Resulted in Economic Growth and Continued Innovation Enacted in 1980, the Bayh-Dole Act created a uniform framework for the sharing of technology between universities and the private sector that has facilitated timely and effective commercialization of federally funded research. POSITIVE IMPACT OF BAYH-DOLE MORE THAN 1,000 startup companies were formed19 NEARLY 800 commercial products stemming from university research were introduced19 ABOUT 4.2 MILLION US jobs supported across all industries20 From 1996 to 2015, licensing activity spurred by Bayh-Dole included: Close to $591 BILLION contributed to US GDP20 Commercialization of federally funded research has increased dramatically. In 2017: 37 2 Research and Development Sources: Association of University Technology Managers19; Pressman L et al.20
Slide 42-

Collaboration Is Key in Researching and Developing New Medicines The rapid pace of scientific and technological advances is propelling a new era in biopharmaceutical innovation in the United States. As the science becomes more complex, partnerships are crucial to advancing biomedical progress. Examples of key collaborative efforts across the R&D spectrum include: Bolstering research to improve prevention and treatment for opioid misuse and addiction and enhancing pain management by developing new biomarkers and a data sharing collaborative24 Using comprehensive genetic screening to identify mutations in lung cancer patients in order to direct them to a specific investigational treatment, while operating under a single clinical trial protocol23 Combining expertise and resources to rapidly identify, develop, and qualify biomarkers, which will then advance new therapies and guide improvements in regulatory and clinical decision making22 Developing new diagnostics and biological targets for treatments in Alzheimer’s disease, type 2 diabetes, rheumatoid arthritis, Parkinson’s disease, and lupus21 THE PARTNERS biopharmaceutical companies, NIH, FNIH, patient and disease organizations THE PARTNERS biopharmaceutical companies, NIH, FDA, patient and disease organizations THE PARTNERS biopharmaceutical companies, NIH, CMS, FDA, FNIH, patient and disease organizations THE PARTNERS biopharmaceutical companies, NIH, patient and disease organizations 38 2 Research and Development Sources: NIH21; FNIH22; Lung-MAP23; NIH24
Slide 43-

350 300 250 200 150 100 50 0 0 2,000 4,000 6,000 8,000 10,000 0 100 200 300 400 500 600 334 2014 34 2005 The number of CONSORTIA increased 9x New R&D PARTNERSHIPS more than doubled 4,000 2005 9,000 2014 Early-stage PARTNERSHIPS more than doubled 578 2014 256 2005 Researchers Are Harnessing Collaborations to Accelerate Innovation In recent years, stakeholders across the biopharmaceutical research ecosystem have shifted to non-asset-based, precompetitive partnership models in order to leverage their strengths in creative ways, create efficiencies, and tackle scientific and technological challenges. 39 2 Research and Development Source: Deloitte25
Slide 44-

PhRMA Member Company R&D Investment $50 $40 $60 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 $20 $15.2 $10 $39.9 $30 $26.0 Expenditures (in Billions) $50.7 PhRMA Member Company R&D Expenditures, 1995-2018 $80 $79.6 $70 $59.6 40 2 Research and Development Source: PhRMA26
Slide 45-

The Costs of Drug Development Have More Than Doubled Over the Past Decade Many factors are driving increasing costs of biopharmaceutical R&D, including increased clinical trial complexity, larger clinical trial sizes, greater focus on targeting chronic and degenerative diseases, and higher failure rates for drugs tested in earlier-phase clinical studies. 1970s 1980s 1990s-Early 2000s 2000s-Early 2010s $413M $179M $1.0B $2.6B AVERAGE COST TO DEVELOP ONE NEW APPROVED DRUG— INCLUDING THE COST OF FAILURES (in Constant 2013 Dollars) 41 2 Research and Development Source: DiMasi JA et al.27
Slide 46-

The Complexity of Clinical Trials Has Increased During the past decade, clinical trial designs and procedures have become much more complex, reducing trial participation and retention rates. 13 7 110 187 50 31 40 65 929,203 494,236 2001-2005 THEN Increase in COMPLEXITY 2011-2015 NOW +86% +70% +61% +63% +88% Endpoints THEN & NOW Clinical Trial Complexity Procedures Eligibility Criteria Investigative Sites Data Points Collected Typical Phase III Protocol (Mean of Total Numbers) 42 2 Research and Development Source: Getz KA et al.28
Slide 47-

'98 '99 '00 '01 '02 '03 '04 '05 '06 '07 146 Total Unsuccessful Drugs 6 13 8 1 0 3 1 7 4 12 15 12 9 5 14 10 10 4 4 1 NEW APPROVAL 1 NEW APPROVAL 1 NEW APPROVAL 1 NEW APPROVAL 8 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 4 Total Approved Medicines Source: PhRMA29 Setbacks in Alzheimer’s Disease Research Provide Stepping Stones for Future Innovation Since 1998, 146 medicines in development for the treatment of Alzheimer’s disease have not made it through clinical trials, with only 4 gaining FDA approval. These setbacks highlight the complexity of the R&D process. Though disappointing, they provide important knowledge to fuel future research. Unsuccessful Investigational Drugs for Alzheimer’s Disease, 1998-2017 43 2 Research and Development
Slide 48-

*Setbacks and advances from 1998 to 2014 MELANOMA* 96 unsuccessful attempts 7 new drugs BRAIN CANCER* 75 unsuccessful attempts 3 new drugs LUNG CANCER* 167 unsuccessful attempts 10 new drugs Cancer Researchers Build on Knowledge Gained From Setbacks to Inform Future Advances Developing a new cancer medicine is a complex process and can take, on average, 1.5 years longer than the development of other medicines. Although the process is fraught with setbacks, some “failures” can inform future study and help guide research efforts. The scientific process is thoughtful, deliberate, and sometimes slow, but each advance, while helping patients, now also points toward new research questions and unexplored opportunities.” — Clifford A. Hudis, MD, FACP30 Chief Executive Officer, American Society of Clinical Oncology Chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College 44 2 Research and Development Sources: Patel JD et al.30; PhRMA31
Slide 49-

Pediatric Clinical Research: Overcoming Challenges The Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) establish requirements and provide important incentives that help increase the number of clinical studies in pediatric populations. These laws spur pediatric research for this vulnerable population. BPCA/PREA Success Since 1998, more than 770 pediatric labeling changes32 Since 2007, more than 680 pediatric studies have been completed33,34 ? Before 1997 >80% of medicines used to treat children did not have pediatric dosing information35 By 2012 That number had been reduced to nearly 50%36 Unique Challenges in PEDIATRIC RESEARCH37 Small patient populations Distinct dosage and formulation requirements Unique ethical, scientiﬁc, and medical considerations Difﬁcult to enroll patients in trials 45 2 Research and Development Sources: FDA32-36; ACS37
Slide 50-

Enhancing the Drug Discovery, Development, and Review Process The 21st Century Cures Act and Prescription Drug User Fee Act help ensure the FDA has the tools and resources needed to better manage the significant emerging science and innovation of today to meet the challenges of tomorrow. INTEGRATING PATIENT PERSPECTIVE Advance patient-focused drug development at the FDA and throughout the clinical trials process through appropriate incorporation of patient input, patient-reported outcomes, and increased patient engagement. ADVANCING USE OF REAL-WORLD EVIDENCE Keep pace with latest technological advances by enabling use of real-world evidence and real-world data in regulatory decision making. INCREASING ACCEPTANCE OF INNOVATIVE CLINICAL TRIAL DESIGNS Create efficiencies in drug development through use of adaptive clinical trial designs and pragmatic clinical trials as well as increased use of advanced data analytics. ACCELERATING QUALIFICATION AND USE OF BIOMARKERS Adapt biomarker qualification development and other regulatory pathways to support the development of emerging cell and gene therapies, personalized medicines, and companion diagnostics. 46 2 Research and Development
Slide 51-

Learning From Patients to Develop Better Treatments As important stakeholders in the drug development process, patients, family members, and caregivers can provide unique and valuable perspectives on the disease and available treatment options. These perspectives can inform evaluation of a medicine’s benefits and risks and provide the context for FDA regulatory decision making. WHO CAN PROVIDE PATIENT PERSPECTIVES? Patients Family Members Caregivers THE FDA incorporates patient perspective into its regulatory decision making. NEW MEDICINES reﬂect patient and caregiver needs. BENEFITS OF PATIENT PERSPECTIVES RESEARCHERS include patient perspective throughout drug development process. 47 2 Research and Development Source: PhRMA38
Slide 52-

Notes and Sources Adis R&D Insight Database. https://adis.springer.com. Accessed May 2019. Adis R&D Insight Database. https://adis.springer.com. Accessed April 2019. Disease-specific numbers are available in PhRMA’s Medicines in Development reports. http://www.phrma.org/science/in-the-pipeline/medicines-in-development. Long G; Analysis Group. The biopharmaceutical pipeline: innovative therapies in clinical development. http://phrma-docs.phrma.org/files/dmfile /Biopharmaceutical-Pipeline-Full-Report.pdf. Published July 2017. Accessed May 2018. Food and Drug Administration (FDA). Search orphan drug designations and approvals. http://www.accessdata.fda.gov/scripts/opdlisting/oopd. Accessed February 2019. Danese E, Lippi G. Rare diseases: the paradox of an emerging challenge. Ann Transl Med. 2018;6(17):329. doi:10.21037/atm.2018.09.04 Pharmaceutical Research and Manufacturers of America (PhRMA). Spurring innovation in rare diseases. http://phrma-docs.phrma.org/files /dmfile/RareDisease_Backgrounder.pdf. 2018 update. Accessed April 2018. Food and Drug Administration (FDA). FDA news release. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. Senate Committee on Health, Education, Labor & Pensions Hearing, “Implementation of the 21st Century Cures Act: Progress and the Path Forward for Medical Innovation.” https://www.fda.gov/news-events/press-announcements/remarks-fda-commissioner-scott-gottlieb -md-prepared-oral-testimony-us-senate-committee-health. Published December 7, 2017. Accessed May 2019. Pharmaceutical Research and Manufacturers of America (PhRMA). Medicines in development for cell therapy and gene therapy. http://phrma -docs.phrma.org/files/dmfile/MID_Cell_and_Gene_Therapy_2018_FINAL.pdf. Accessed April 2019. Avalere Health. A conversation on digital health [webinar]. https://avalere.com/webinars/a-conversation-on-digital-health. Published April 2019. Accessed April 2019. Personalized Medicine Coalition. Personalized medicine at FDA: a progress and outlook report 2018. http://www.personalizedmedicinecoalition .org/Userfiles/PMC-Corporate/file/PM_at_FDA_A_Progress_and_Outlook_Report.pdf. Accessed April 2019. Tufts Center for the Study of Drug Development (CSDD). Personalized medicine gains traction but still faces multiple challenges. Tufts CSDD Impact Rep. 2015;17(3). PhRMA adaptation of DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33. Tufts Center for the Study of Drug Development (CSDD). Cost of developing a new drug [briefing]. https://csdd.tufts.edu/csddnews/2018/3/9 /march-2016-tufts-csdd-rd-cost-study. Published November 18, 2014. Accessed May 2018. 48 2 Research and Development
Slide 53-

Notes and Sources Food and Drug Administration (FDA). U.S. Food and Drug Administration drug approval process. http://www.fda.gov/downloads/Drugs /ResourcesForYou/Consumers/UCM284393.pdf. Accessed May 2017. Chakravarthy R, Cotter K, DiMasi J, et al. Public- and private-sector contributions to the research and development of the most transformational drugs in the past 25 years: from theory to therapy. Ther Innov Regul Sci. 2016;50(6):759-768. Chakravarthy R, Cotter K, DiMasi J, et al. Public- and private-sector contributions to the research and development of the most transformational drugs in the past 25 years: from theory to therapy. Ther Innov Regul Sci. 2016;50(6):759-768. Research!America. U.S. investments in medical and health research and development, 2013-2017. https://www.researchamerica.org/sites /default/files/Policy_Advocacy/2013-2017InvestmentReportFall2018.pdf. Published 2018. Accessed April 2019. National Institutes of Health (NIH). Overall appropriations. https://officeofbudget.od.nih.gov/pdfs/FY18/Overall%20Appropriations.pdf. Accessed April 2019. Association of University Technology Managers. AUTM US licensing activity survey: 2017. https://autm.net/AUTM/media/SurveyReportsPDF /AUTM_2017_US_Licensing_Survey_no_appendix.pdf. Accessed April 2019. Pressman L, Planting M, Yuskavage R, et al. The economic contribution of university/nonprofit inventions in the United States: 1996-2015. https://www.autm.net/AUTMMain/media/Partner-Events/Documents/Economic-_Contribution_University-Nonprofit_Inventions_US_1996 -2015_BIO_AUTM.pdf. Published June 2017. Accessed April 2018. National Institutes of Health (NIH). Accelerating Medicines Partnership (AMP). https://www.nih.gov/research-training/accelerating-medicines -partnership-amp. Accessed April 2019. Foundation for the National Institutes of Health (FNIH). Biomarkers Consortium. https://fnih.org/what-we-do/biomarkers-consortium. Accessed April 2019. Lung-MAP. About Lung-MAP. http://www.lung-map.org/about-lung-map. Accessed April 2019. National Institutes of Health (NIH). NIH HEAL Initiative. https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative. Accessed April 2019. Lesser N, Hefner M; Deloitte. Partnering for progress: how collaborations are fueling biomedical advances. https://www2.deloitte.com/content /dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-partnering-for-progress-how-collaborations-are-fueling-biomedical-advances.pdf. Published 2017. Accessed June 2017. Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA Annual Membership Survey, 1996-2018. Washington, DC: PhRMA; 2019. 49 2 Research and Development
Slide 54-

Notes and Sources DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33. Previous research by DiMasi and Grabowski estimated the average R&D costs in the early 2000s at $1.2 billion in constant 2000 dollars (see DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? MDE Manage Decis Econ. 2007;28:469-479). That estimate is based on the same underlying survey as estimates for the 1990s to early 2000s reported here ($800 million in constant 2000 dollars) but is updated for changes in the cost of capital. Getz KA, Campo RA. New benchmarks characterizing growth in protocol design complexity. Ther Innov Regul Sci. 2018;52(1):22-28. Pharmaceutical Research and Manufacturers of America (PhRMA). Researching Alzheimer’s medicines: setbacks and stepping stones. http:// phrma-docs.phrma.org/files/dmfile/AlzheimersSetbacksSteppingStones_FINAL_digital.pdf. Published 2018. Accessed April 2019. Patel JD, Krilov L, Adams S, et al. Clinical cancer advances 2013: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2014;32(2):129-160. http://jco.ascopubs.org/content/early/2013/12/09/JCO.2013.53.7076.full.pdf+html. Accessed May 2017. Pharmaceutical Research and Manufacturers of America (PhRMA). Researching cancer medicines: setbacks and stepping stones. http://www .phrma.org/sites/default/files/pdf/2014-cancer-setbacks-report.pdf. Published 2014. Accessed May 2017. Food and Drug Administration (FDA). New pediatric labeling information database. https://www.accessdata.fda.gov/scripts/sda/sdnavigation .cfm?filter=&sortColumn=1a&sd=labelingdatabase&page=1. Current as of March 31, 2019. Accessed May 2019. Food and Drug Administration (FDA). Pediatric studies characteristics. https://www.accessdata.fda.gov/scripts/SDA/sdNavigation.cfm?filter =&sortColumn=1a&sd=fdaaadescriptorssortablewebdatabase&displayAll=false&page=8. Accessed May 2019. Food and Drug Administration (FDA). Number of pediatric studies completed (under both PREA and BPCA). https://www.accessdata.fda.gov /scripts/fdatrack/view/track.cfm?program=cder&status=public&id=CDER-RRDS-Number-of-pediatric-studies-completed&fy=All. Current as of December 31, 2017. Accessed April 2018. Food and Drug Administration (FDA). Drug research and children. https://www.fda.gov/drugs/drug-information-consumers/drug-research-and -children. Current as of May 4, 2016. Accessed May 2019. Karesh A; Food and Drug Administration (FDA). Pediatric drug development: regulatory expectations basic. https://www.fda.gov/media /91673/download. Accessed May 2019. American Cancer Society (ACS). Translating discovery into cures for children with cancer: childhood cancer research landscape report. https:// www.cancer.org/content/dam/cancer-org/research/translating-discovery-into-cures-for-children-with-cancer-landscape-report.pdf. Published 2016. Accessed May 2017. Pharmaceutical Research and Manufacturers of America (PhRMA). Patient-focused drug development. https://www.phrma.org/fact-sheet /patient-focused-drug-development. Published June 2016. Accessed May 2019. 50 2 Research and Development
Slide 55-

Photo placeholder 51
Slide 56-

Photo placeholder 52
Slide 57-

53 MARKET DYNAMICS The Economics of Drug Development and the Market Forces That Shape Spending on Medicines Competition is a hallmark of the US prescription medicines market. Negotiating power is concentrated among a few pharmacy benefit managers (PBMs), which forces new medicines to compete for coverage and increases the likelihood of excluding medicines from coverage altogether. The built-in cost containment of the prescription drug lifecycle remains unique in health care, where new medicines eventually lead to lower-cost generics—and soon many biosimilars—that bring long-term value to patients. Ongoing investment in research and development (R&D) depends on the commercial success of a few products that must make up for all the rest, including those that never reach the market. Average returns on R&D investments have been declining. Accounting for uncertainty and risk, biopharmaceutical industry profits are in the middle range among all industries. The market is rapidly evolving, increasingly linking payment to results and affecting how drugs are prescribed. Value-based contracts and other market-based arrangements show promise for improving outcomes and reducing costs. 3 53
Slide 58-

Illustrative Pharmaceutical Lifecycle New pharmaceutical medicines typically face competition after a relatively short time on the market, first from brand competitors, and eventually from generics. Most brands already have at least one brand competitor when they enter the market or get one within 2 years.2 FDA Approval Generics Enter Market BRAND DRUG LIFESPAN* Average time on market before generic entry: 12.5 years4** DRUG DEVELOPMENT Average time to develop a new medicine: At least 10-15 years3 GENERICS Generics remain in use for many years at a small fraction of the original brand's cost. *Brand drug market share generally declines rapidly after generic entry. **For brand medicines with more than $250 million in annual sales in 2008 dollars, which account for 92% of sales of the brand medicines analyzed 54 3 Market Dynamics Sources: PhRMA1; DiMasi JA et al.2,3; Grabowski H et al.4
Slide 59-

Medicines Offer Built-in Cost Containment, Which Is Unique in Health Care The price of a medicine commonly used to prevent cardiovascular disease dropped 90% between 2005 and 2015, while the average charge for a surgical procedure to treat it increased 92% over the same period. $47,692 $92,251 $2.13 $0.22 2005 2015 2005 2015 Percutaneous Coronary Angioplasty5 Atorvastatin 10mg6 -90% +92% 55 3 Market Dynamics Sources: PhRMA analysis of HCUP Hospital Charge data5; IQVIA6
Slide 60-

Powerful Purchasers Negotiate on Behalf of Payers Negotiating power is increasingly concentrated among fewer pharmacy benefit managers (PBMs), each purchasing medicines for more people than the populations of entire European countries. 56 3 Market Dynamics Source: Drug Channels Institute7
Slide 61-

2019 2018 2017 2016 2015 2014 2013 2012 38 50 72 95 124 154 154 48 66 87 85 196 0 0 173 When a medicine is excluded from a pharmacy benefit manager’s (PBM’s) formulary, patients cannot access it without paying the list price. This can interrupt the continuity of a patient’s treatment as well as their doctor’s ability to make prescribing decisions that best meet their patients’ needs.8 Number of Brand Medicines Excluded From PBM Formulary9 242 Express Scripts CVS Caremark Number of Brand Medicines Excluded From PBM Formularies Has Increased Over Time 57 3 Market Dynamics Sources: Tufts CSDD8; Drug Channels Institute9
Slide 62-

Case Study in Manufacturer-Payer Negotiations: Hepatitis C Medicines Leveraging increased competition in the hepatitis C market, payers negotiated deep discounts off list prices for new medicines with manufacturers, reducing prices below those in many Western European countries.10 What Payers Claimed Would Happen What Actually Happened “What they have done with this particular drug will break the country.... It will make pharmacy benefits no longer sustainable. Companies just aren’t going to be able to handle paying for this drug.” — Express Scripts, April 201411 “This pricing, which Gilead attempts to justify as the cost of medical advancement, will have a tsunami effect across our entire health care system.” — America’s Health Insurance Plans, July 201412 “The price is sufficiently low that we can go to our clients and say that they can treat every patient with hepatitis C.” — Express Scripts, January 201513 “We are receiving market-leading rates from both companies. Neither company wanted to be left off the formulary.” — Prime Therapeutics, January 201514 “Competitive market forces and hard-nosed bargaining make ‘tremendously effective’ new hepatitis C medicines not just more accessible to ailing patients—but also offer good value to the U.S. health care system.” — The New York Times Editorial Board, September 201515 58 3 Market Dynamics Sources: LaMattina J10; Cortez MF11; Ignagni K12; Silverman E13; Langreth R14; New York Times Editorial Board15
Slide 63-

Brand-to-Brand Competition Drives Savings in US Market-Based System -36% -30% -83% 2$013 2$013 2$018 2$016 2$018 2$018 Payers leverage purchasing power and competition among brand medicines to negotiate substantial discounts on medicines. Avg. Net Brand Price Cholesterol PCSK9 inhibitors Type 2 Diabetes SGLT2 inhibitors Hepatitis C Direct-acting antivirals First in class* 6 drugs in class 3 drugs in class 2 drugs in class First in class* First in class* *Indicates launch year of the first drug in this pharmacologic class. 59 3 Market Dynamics Source: PhRMA analysis of SSR health data16
Slide 64-

*A “medicine” is defined as a novel active substance (ie, a molecular or biologic entity or combination product in which at least one element had not been previously approved by the FDA). Sales are global sales, net of rebates and discounts. Few Approved Medicines Are Commercially Successful Ongoing investment in R&D depends on the commercial success of a few products that must make up for all the rest, including those that never reach the market. Present Value of Lifetime Sales of Medicines* Introduced, 1991-2009 $60 $50 $40 $30 $20 $10 $0 10% 20% 30% 70% 60% 50% 40% Percentile of Lifetime Sales Revenues 80% 90% 100% 2005 Dollars (in Billions) 60 3 Market Dynamics Source: Berndt ER et al.17
Slide 65-

*All numbers are 3-year moving averages for brand medicines with more than $250 million in annual sales in 2008 dollars, which account for 92% of sales of the brand medicines analyzed. Earlier and More Frequent Patent Challenges by Generic Companies As early as 4 years after brand launch, a generic company may file a Paragraph IV certification with the FDA to challenge patents associated with the brand medicine, often allowing generic market entry before the patent expiration date. 25 20 15 10 5 0 Patent challenges are occurring earlier... Average Time From Brand Launch to Paragraph IV Patent Challenge* Brands by Year of First Generic Entry Number of Years ...and are more common Share of Brand Products Experiencing at Least 1 Paragraph IV Patent Challenge Prior to Generic Entry* Brands by Year of First Generic Entry 61 3 Market Dynamics Source: Grabowski H et al.18
Slide 66-

12.4% 6.0% 5.9% 5.4% 7.6% 7.4% 14.6% 28.3% 63.7% 38.3% Advertising Health Care Support Services Aerospace/Defense Auto Parts Food Wholesalers Health Care IT Software (Internet) Retail (General) Electronics (General) Biopharmaceutical** Construction Supplies Farming/Agriculture -1.0% -1.9% 4.5% 2.2% Telecom (Wireless) Shipbuilding/Marine Biopharmaceutical Profits Are in Line With Those of Other Industries Adjusted for the significant risk and capital investments required to develop medicines, biopharmaceutical industry profits are average among industries. Average Economic Profit for Selected Industries, 2016-2018* *Economic profits are accounting profits minus capital expenses. **Represents the weighted average of pharmaceuticals (8.2%) and biotechnology (2.2%), which are listed as separate industries in the source data. 62 3 Market Dynamics Source: Adapted from Bates White19
Slide 67-

Increasingly Complex Science and Challenging Markets Have Led to Diminishing Returns on Research Investments Despite headlines about large revenues from new drug launches, biopharmaceutical companies have faced declining financial returns on their R&D investments. Projected Internal Rate of Return for R&D Investments, 2010-2018 0% 5% 10% 15% 20% 2018 2014 2015 2016 2017 2011 2012 2013 12 Large Cap Biopharma Companies 2010 10.1% 7.6% 7.3% 4.8% 5.5% 4.2% 3.7% 3.2% 1.9% 17.4% 17.7% 16.1% 11.0% 12.5% 9.3% 4 Smaller, Specialized Biopharma Companies 63 3 Market Dynamics Source: Deloitte20
Slide 68-

PBM Profit Margins Are Well Above Others in the Drug Distribution and Supply Chain Pharmacy benefit managers (PBMs) do not take possession of the medicines they manage, keeping their spending on fixed assets and other expenses very low. Their resulting profits are even higher than manufacturers’ profits, despite bearing very little risk. Share of Gross Profit Converted to EBITDA, 2016-2017* *Calculated as EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin divided by gross margin Analysts at Bernstein tried to get a better picture of how profitable these [supply chain] companies are by excluding the cost of the drugs that are included in their revenue... By this analysis, pharmacy- benefit managers are exceptionally profitable.” — Charley Grant, Wall Street Journal 23 0% 20% 40% 60% 80% 100% PBMs Distributors Manufacturers Insurers Pharmacies 85% 46% 31% 29% 44% 64 3 Market Dynamics Sources: Bernstein Research21; NDP Analytics22; Grant C23
Slide 69-

Fees Paid to PBMs Have Increased Significantly $0 $5 $10 $15 $20 While pharmacy benefit managers (PBMs) have retained a smaller share of total rebates, they have offset lost profit from rebates with increased fees. In 2016, PBM revenue surpassed $22 billion, nearly twice the 2012 PBM revenue of $11.6 billion. Fees paid to PBMs quadrupled between 2014 and 2016 alone. PBM Revenue by Source (in Billions), 2012-2016 $25 Part D Fees to PBM Commercial Health Plan Fees to PBM Manufacturer Fees to PBM PBM Supply Chain Margin From Pharmacy Retained Manufacturer Rebates 2016 2015 2014 2013 2012 Total Fees $11B 65 3 Market Dynamics Source: Pew Charitable Trusts24
Slide 70-

Accounting Treatment of R&D Overstates Biopharmaceutical Profits Correctly accounting for R&D as a long-lived investment tends to reduce substantially, if not to eliminate altogether, the inference that pharmaceutical companies are on average achieving supranormal profit returns.” — Frederic Scherer, AEI-Brookings Joint Center for Regulatory Studies25 [T]he standard accounting measure of profits overstates true returns to R&D-intensive industries, such as pharmaceuticals, and makes it difficult to meaningfully compare profit levels among industries. Accounting measures treat most R&D spending (except for capital equipment) as a deductible business expense rather than as a capitalized investment. But the intangible assets that research and development generate—such as accumulated knowledge, new research capabilities, and patents—increase the value of a company’s asset base. Not accounting for that value overstates a firm’s true return on its assets.” — Congressional Budget Office26 66 3 Market Dynamics Sources: Scherer FM25; CBO26
Slide 71-

Hospitals Mark Up Medicines in the Outpatient Setting, Driving Up Costs to Patients and the Health System Hospitals mark up medicine prices, on average, nearly 500%. The amount hospitals receive after negotiations with commercial payers is, on average, more than 250% what they paid to acquire the medicine.27 Percentage of Hospitals by Average Level of Markup for Medicines* (3,792 Hospitals) 11% 20% 19% 14% 9% 6% 4% 3% 2% 2% 8% On a medicine with an ASP** of $150, this could result in a charge of $1,050 or more.28 marks up medicines to 700% or more of their acquisition costs. out of Nearly 1 every 5 hospitals <100% 100-199% 200-299% 300-399% 400-499% 500-599% 600-699% 700-799% 800-899% 900-999% >1000% Average Charge-to-Cost Ratio for Medicines *Percentages in chart may not add up to 100% due to rounding. **ASP: Average Sales Price 67 3 Market Dynamics Sources: The Moran Company27,28
Slide 72-

Direct-to-Consumer Advertising Increases Awareness of Conditions and Treatments A recent survey of consumers demonstrated the positive contribution of direct-to-consumer (DTC) advertising to patients’ knowledge. How strongly do you agree or disagree with each statement? Percentage who AGREE with each statement (Survey of 1,564 consumers, April 2017) ...allow people to be more involved in their health care ...alert people to symptoms that are related to a medical condition they may have ...tell people about new treatments 88% 81% 79% DTC ads 68 3 Market Dynamics Source: Princeton Survey Research Associates International29
Slide 73-

Clinical Factors Are the Biggest Driver of Physicians’ Prescribing Decisions Factors Influencing Physicians’ Prescribing Decisions in the United States, 2013 Information from insurance and prescription beneﬁts manager representatives Information from pharmaceutical company representatives Pharmaceutical company-sponsored educational programs featuring physician speakers, not Continuing Medical Education Information from colleagues and peers Patient’s particular situation, including drug interactions, Clinical knowledge and experience 91% 8% 9% 38% 54% 11% 47% 10% 53% 10% 35% A great deal Some 69 3 Market Dynamics Source: KRC Research30
Slide 74-

Biopharmaceutical Company Marketing and Promotion Spending in Context Marketing and Promotion Research and Development EXCLUDES: Freight Costs Other Unrelated G&A Expenses* Use of inflated estimates of marketing and promotion spending has created the false impression that the biopharmaceutical industry spends more on marketing than on R&D. More precise estimates show the opposite to be true. Select US Biopharmaceutical Industry Expenses, 2016 $90.5B INCLUDES: Advertising to Consumers Advertising to Health Care Professionals Sales Representatives $28.1B *Indicates general and administrative (G&A) expenses unrelated to marketing and promotion, such as ﬁnance and ofﬁce staffs, rent, utilities, and supplies. Some have inaccurately used sales and G&A expenses as a proxy for industry marketing and promotion expenses. Sources: Schwartz L et al.31; Research!America32 70 3 Market Dynamics
Slide 75-

Increasing Provider Accountability for Cost of Care and Pathway Implementation Is Influencing Prescribing Decisions THEN NOW *Only represents fee-for-service and is a conservative estimate Sources: Health Strategies Insights by EVERSANA33; American Hospital Association34,35; HHS36; HCP LAN37; Catalyst for Payment Reform38 71 3 Market Dynamics
Slide 76-

Value-Based Contracts Deliver Results for Patients Value-based contracts have the potential to benefit patients and the health care system by improving patient outcomes, reducing medical costs, and reducing the costs of medicines. We’ve been able to get the best of both worlds. The insurer gets competitive guaranteed discounts on prescriptions, and the manufacturer is aligned and accountable when something doesn’t work.” — Chris Bradbury, Cigna40 Outcomes-Based Contracts are associated with 28% lower patient copayments. Value-Based Contracts could generate more than $12 Billion if they reduced the diabetes burden in the United States by only 5%. 72 3 Market Dynamics Sources: PhRMA39; Hopkins JS et al.40
Slide 77-

Innovative Market-Based Arrangements That Link Payment for Medicines to Outcomes Are on the Rise Oncology Neuromuscular Disorder Metabolic Disorder Cardiovascular Autoimmune All Others 2018-2022 2013-2017 11 27 17 24 3 2 6 1 1 8 4 8 New US Publicly Announced Outcomes-Based Contracts and Projected Future Increase 65 The number of publicly announced outcomes-based contracts is expected to more than double by 2022. 73 3 Market Dynamics Source: IQVIA Institute41
Slide 78-

Notes and Sources Pharmaceutical Research and Manufacturers of America (PhRMA). Drug Discovery and Development: Understanding the R&D Process. Washington, DC: PhRMA; 2014. DiMasi JA, Chakravarthy R. Competitive development in pharmacologic classes: market entry and the timing of development. Clin Pharmacol Ther. 2016;100(6):754-760 DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33. Grabowksi H, Long G, Mortimer R, et al. Updated trends in US brand-name and generic drug competition. J Med Econ. 2016;19(9):836-844. Average hospital charge data from Healthcare Cost and Utilization Project (HCUP) Hospital Charge Database 2005, 2013, and 2015. https:// www.ahrq.gov/research/data/hcup/index.html. Accessed May 2018. Invoice price data for atorvastatin 10mg from IQVIA National Sales Perspectives data for 2005 (branded Lipitor) and 2015 (generic). https://www .iqvia.com/locations/united-states/commercial-operations/essential-information/sales-information. Accessed May 2018. Fein AJ; Drug Channels Institute. The 2019 economic report on U.S. pharmacies and pharmacy benefit managers. https://www.drugchannels .net/2019/03/new-2019-economic-report-on-us.html. Published March 2019. Accessed March 2019. Tufts Center for the Study of Drug Development (CSDD). Rapid growth in PBM exclusion lists poses challenge to drug developers. Tufts CSDD Impact Rep. 2016;18(3). https://csdd.tufts.edu/s/Summary-MayJunIR2016.pdf. Accessed May 2019. Fein AJ; Drug Channels Institute. The 2019 economic report on U.S. pharmacies and pharmacy benefit managers. https://www.drugchannels .net/2019/03/new-2019-economic-report-on-us.html. Published March 2019. Accessed March 2019. LaMattina J. For hepatitis C drugs, U.S. prices are cheaper than in Europe. Forbes. http://www.forbes.com/sites/johnlamattina/2015/12/04/for -hepatitis-c-drugs-u-s-prices-are-cheaper-than-in-europe/#7ced43f564bb. Published December 4, 2015. Accessed May 2017. Citing comments made at Forbes Healthcare Summit 2015. Cortez MF. Express Scripts raises pressure on Gilead for drug price. Bloomberg. https://www.bloomberg.com/news/articles/2014-04-08 /express-scripts-raises-pressure-on-gilead-for-drug-price. Published April 8, 2014. Accessed May 2018. Ignagni K. We all pay for $1,000 a pill drug. CNN. http://edition.cnn.com/2014/07/07/opinion/ignagni-hepatitis-c-drug. Published July 24, 2014. Accessed May 2017. Silverman E. ‘The big issue has not been choice, but access:’ Express Scripts’ Miller explains. Wall Street Journal. http://blogs.wsj.com/pharmalot /2015/01/06/the-big-issue-has-not-been-choice-but-access-express-scripts-miller-explains. Published January 6, 2015. Accessed May 2017. 74 3 Market Dynamics
Slide 79-

Notes and Sources Langreth R. Hepatitis drug prices fall so low, no exclusives needed. Bloomberg. https://www.bloomberg.com/news/articles/2015-01-12/prime -covers-both-gilead-and-abbvie-liver-drugs-as-prices-plunge. Published January 12, 2015. Accessed May 2018. New York Times Editorial Board. Costly hepatitis C drugs for everyone? New York Times. https://www.nytimes.com/2015/09/02/opinion/costly -hepatitis-c-drugs-for-everyone.html?_r=0. Published September 2, 2015. Accessed May 2017. SSR health data. http://www.ssrhealth.com/research-archive. April 2019. Berndt ER, Nass D, Kleinrock M, et al. Decline in economic returns from new drugs raises questions about sustaining innovations. Health Aff. 2015;34(2):245-252. Grabowksi H, Long G, Mortimer R, et al. Updated trends in US brand-name and generic drug competition. J Med Econ. 2016;19(9):836-844. Adapted by PhRMA from Bates White. Economic profitability of the biopharmaceutical industry. Report for PhRMA, June 2018. Updated data tables April 2019. Economic profit for each industry is calculated as: (net operating profit less adjusted taxes) - (invested capital x weighted average cost of capital). Deloitte Centre for Health Solutions. Unlocking R&D productivity: measuring the return from pharmaceutical innovation 2018. https://www2 .deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/deloitte-uk-measuring-return-on-pharma-innovation -report-2018.pdf. Published December 2018. Accessed May 2019. Wilkes L; Bernstein Research. US healthcare services: Amazon—dual threats to healthcare services and their implications to the sector including ESRX [subscription analyst report]. February 22, 2018. Pham ND; NDP Analytics. Prescription drug supply chain profitability. http://www.ndpanalytics.com/s/Prescription-Drug-Supply-Chain -Profitability-102518-Final-ykak.pdf. Published October 2018. Accessed April 2019. Grant C. Hidden profits in the prescription drug supply chain. Wall Street Journal. https://www.wsj.com/articles/hidden-profits-in-the -prescription-drug-supply-chain-1519484401. Published February 24, 2018. Accessed May 2018. Pew Charitable Trusts. The prescription drug landscape, explored. https://www.pewtrusts.org/en/research-and-analysis/reports/2019 /03/08/the-prescription-drug-landscape-explored. Published March 2019. Accessed May 2019. Scherer FM. Pharmaceutical innovation. AEI-Brookings Joint Center for Regulatory Studies Working Paper 07-13. July 2007. https://papers .ssrn.com/sol3/papers.cfm?abstract_id=902395##. Published July 2007. Accessed May 2018. Congressional Budget Office (CBO). Research and development in the pharmaceutical industry. http://www.cbo.gov/sites/default/files /cbofiles/ftpdocs/76xx/doc7615/10-02-drugr-d.pdf. Published October 2006. Accessed May 2017. 75 3 Market Dynamics
Slide 80-

Notes and Sources The Moran Company; for PhRMA. Hospital charges and reimbursement for drugs: analysis of markups relative to acquisition cost. http://www .themorancompany.com/wp-content/uploads/2017/10/Hospital-Charges-Report-2017_FINAL.pdf. Published October 2017. Accessed May 2018. The Moran Company; for PhRMA. Hospital charges and reimbursement for medicines: analysis of cost-to-charge ratios. http://www .themorancompany.com/wp-content/uploads/2018/09/Hospital-Charges-Reimbursement-for-Medicines-August-2018.pdf. Published September 2018. Accessed April 2019. Survey conducted by Princeton Survey Research Associates International for PhRMA. April 2017. KRC Research; for PhRMA. Survey of Physicians About Pharmaceutical and Biotech Research Company Activities and Information: Nationally Representative Survey of 502 Physicians. Washington, DC: KRC Research; February 2014. Schwartz LM, Woloshin S. Medical marketing in the United States, 1997-2016. JAMA. 2019;321(1):80-96. Research!America. U.S. investments in medical and health research and development, 2013-2017. https://www.researchamerica.org/sites /default/files/Policy_Advocacy/2013-2017InvestmentReportFall2018.pdf. Published 2018. Accessed May 2019. Health Strategies Insights by EVERSANA. Health plan oncology pathways insight and evolution. May 2018. American Hospital Association. AHA Hospital Statistics. 2016 ed. Chicago, IL: Health Forum; 2016. American Hospital Association. Accountable care organizations. https://www.aha.org/accountable-care-organizations-acos. Accessed May 2019. US Department of Health and Human Services (HHS). HHS reaches goal of tying 30 percent of Medicare payments to quality ahead of schedule [press release]. https://mountsinaihealth.me/file/2016/05/HHS-reaches-goal-of-tying-30-percent-of-Medicare-payment-to-quality-ahead -of-schedule.pdf. Published March 3, 2016. Accessed May 2019. Health Care Payment Learning & Action Network (HCP LAN). Measuring progress: adoption of alternative payment models in commercial, Medicaid, Medicare Advantage, and Fee-for-Service Medicare programs. https://hcp-lan.org/2018-apm-measurement. Published October 22, 2018. Accessed May 2019. Catalyst for Payment Reform. 2014 national scorecard on payment reform. https://www.catalyze.org/product/2014-national-scorecard. Published 2014. Accessed May 2019. Pharmaceutical Research and Manufacturers of America (PhRMA). Delivering results for patients: the value of value-based contracts. https:// www.phrma.org/report/delivering-results-for-patients-the-value-of-value-based-contracts. Published February 26, 2018. Accessed May 2018. 76 3 Market Dynamics
Slide 81-

Hopkins JS, Langreth R, Paton J. Big pharma’s offer to Trump: discounts when drugs don’t work. Bloomberg. https://www.bloomberg.com/news /articles/2017-02-06/big-pharma-s-offer-to-trump-discounts-when-drugs-don-t-work. Published February 6, 2017. Accessed June 2018. IQVIA Institute for Human Data Science. Medicine use and spending in the U.S.: a review of 2017 and outlook to 2022. https://www.iqvia.com /institute/reports/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022. Published April 19, 2018. Accessed April 2018. Notes and Sources 77 3 Market Dynamics
Slide 82-

Photo placeholder 78
Slide 83-

COST SHARING TRENDS Evaluating the Impact of Insurance Benefit Design on Patients Insurers are increasingly using high deductibles, coinsurance, and multiple cost sharing tiers, which push more costs to some patients. Out-of-pocket spending for prescription medicines can represent a disproportionate share of total health care costs borne directly by patients, especially those who are low income or chronically ill. High cost sharing for medicines may limit patients’ access to needed treatments, reduce adherence, and lead to poor health outcomes. Manufacturer cost sharing assistance can help patients afford their medicines and lower abandonment rates. 4 79 79
Slide 84-

Insurance Covers a Lower Share of Prescription Drug Costs Than Hospital Care Costs On average, patients pay out of pocket 12% of their prescription drug costs compared with 4% of costs for hospital care. Meanwhile, hospital care as a percentage of US health care expenditures is significantly larger than outlays on medicines. Average Share of Health Care Costs Patients Pay Out of Pocket, All Ages1 10% of US Health Care Expenditures2 Analysis includes individuals with any source of health care coverage, public or private; this includes individuals who had health coverage without coverage for prescription drugs, which can be expected to account for less than 2% of those with health coverage. Prescription drug spending includes spending on brand and generic drugs, pharmacy, and distribution costs for retail prescriptions. Note: Prescription drug out-of-pocket costs are based on gross medicine price, not the net price after rebates. Sources: Avalere analysis of Medical Expenditure Panel Survey, 20161; CMS2 Prescription Drugs Hospital Emergency Room Hospital Outpatient Hospital Inpatient Average, All Hospital (4%) 80 4 Cost Sharing Trends
Slide 85-

Patient Spending Rises as Plans Use More Deductibles and Coinsurance Trends in health plan design—toward higher deductibles, coinsurance, and decreased use of copayments—have shifted costs to patients at a higher rate than overall health plan costs. Change Among Large Employer Health Plans, 2006-2016 200% -50% 0% 50% 100% 150% Overall Cost of Covered Beneﬁts* Patient Out- of-Pocket Spend on Copayments Patient Out- of-Pocket Spend on Coinsurance Patient Out- of-Pocket Spend on Deductible 176% 67% -38% 49% Change in Average Payments *Patient out-of-pocket costs are growing faster than overall costs of benefits. 81 4 Cost Sharing Trends Source: Kaiser Family Foundation3
Slide 86-

Share of Employer-Sponsored Health Plans With a Prescription Drug Deductible Is Increasing The percentage of employer-sponsored plans requiring deductibles for pharmacy benefits continues to increase. Percentage of Plans With Deductibles for Prescription Drugs +126% 52% 23% 2012 2017 82 4 Cost Sharing Trends Source: PwC4
Slide 87-

Plans Increasingly Subject Certain Medicines to Higher Cost Sharing Increased use of 4 or more tiers by plans means that more patients are subject to what is commonly higher cost sharing on the specialty tier. Medicines on the specialty tier are also more likely to be subject to coinsurance than products placed on lower cost sharing tiers.5 The use of 4 or more cost sharing tiers is becoming more common in employer plans. For fourth tier6* *52% of plans with coinsurance for the fourth tier have a maximum amount. Average coinsurance 31% Average copay $105 Share of Workers in Plans With 4 or More Tiers6 3% 2004 2006 2008 2010 2012 2014 2015 2016 2017 2018 5% 7% 13% 14% 20% 23% 32% 44% 51% 83 4 Cost Sharing Trends Sources: Kaiser Family Foundation5,6
Slide 88-

Patients Facing High Cost Sharing Commonly Do Not Initiate Treatment Chronic myeloid leukemia patients facing high out-of-pocket costs for medicines on a specialty tier are less likely to initiate drug therapy than patients receiving a cost sharing subsidy, and these patients take twice as long to initiate treatment. Percentage of Chronic Myeloid Leukemia Patients Initiating Treatment 6 months 3 months Time Following Diagnosis 1 month 21% 53% 36% 65% 45% 67% Patients facing high cost sharing Patients facing minimal cost sharing 84 4 Cost Sharing Trends Source: Doshi JA et al.7
Slide 89-

High Cost Sharing Reduces Adherence RAND researchers found that doubling copays reduced patients’ adherence to prescribed medicines by 25%-45% and increased emergency room visits and hospitalizations. Percentage Change in Adherence From Doubling Medicine Copays, by Drug Class -50% -40% -30% -20% -10% 0% Antidiabetics Antidepressants Antihypertensives Antiasthmatics Antiulcerants Antihyperlipidemics Anti-inﬂammatories Percentage Change in Days Supplied of Medicine 85 4 Cost Sharing Trends Source: Goldman DP et al.8
Slide 90-

Cost Sharing Is Based on the Undiscounted List Price When Patients Pay for Brand Drugs With Coinsurance or in a Deductible 26% 29% 44% 55% Share of Patient Out-of-Pocket Spending* Copay Deductible Coinsurance *Percentages may not add up to 100% due to rounding. In 2017, more than half of commercially insured patients’ out- of-pocket spending for brand medicines was based on list price. 86 4 Cost Sharing Trends Source: IQVIA9
Slide 91-

Cost Exposure for Brand Medicines Is Becoming More Prevalent Over Time In 2017, 7% of claims for brand medicines had cost sharing of $125 or more, and these claims now represent more than half of total patient cost exposure. Share of Total Patient Cost Exposure Accounted for by $125+ Claims (Commercial Claims; Brands; 2013-2017) 100% 0% 20% 40% 60% 80% 2017 2016 2015 2014 2013 33% 38% 45% 49% 53% 87 4 Cost Sharing Trends Source: IQVIA10
Slide 92-

As Cost Sharing Rises, Patients Are More Likely to Abandon Their New Medicines New Patient Abandonment by Final Out-of-Pocket Cohort* (Commercial Claims; PayCo® Brands; 2017) 80% 70% 60% 50% 40% 30% 20% 10% 0% $250.01+ $125.00-$250.00 $75.00-$124.99 $50.00-$74.99 $40.00-49.99 $30.00-$39.99 $20.00-$29.99 $10.00-$19.99 $0.00-$9.99 Percentage of Patient Abandonment *Sample is limited to new patient approvals across top brands, which span over 25 traditional and specialty therapeutic areas. 88 4 Cost Sharing Trends Source: IQVIA11
Slide 93-

Patients Who Abandon Prescriptions Often Do Not Initiate Another Therapy Most patients who abandon a brand drug do not fill another drug prescription within 90 days, indicating that they may not be receiving any treatment for their condition. New Patient Abandonment, Subsequent Fill (Brands, 2014) Pulmonary Combination GLP-1 DPP-4 Long-Acting Insulin 78% 80% 79% 81% Fill nothing Fill other product Fill within 60 days Fill within 90 days 89 4 Cost Sharing Trends Source: IMS Institute for Healthcare Informatics12
Slide 94-

Manufacturer Cost Sharing Assistance Cards Can Help Offset Patient Abandonment Patient abandonment rates increase with out-of-pocket costs, but manufacturer cost sharing assistance, like copay cards, reduces patient out-of-pocket costs, which lowers abandonment rates. New Patient Abandonment Trend Comparing Current and Adjusted Copay Card for Patients (Commercial Claims; PayCo® Brands) 2015 2016 2017 Adjusted Abandonment Rate of Copay Card for Patients Without Assistance 2014 Copay Card Patient Abandonment Rate 15% 27% 14% 28% 14% 31% 12% 31% 90 4 Cost Sharing Trends Source: IQVIA13
Slide 95-

Without Coupons, Patients Would Face Higher Average Out-of-Pocket Costs per Prescription *Averages are calculated among paid claims where a copay card is used as the secondary payer and normalized to 30 days. Each January, patients in the commercial market with deductibles face steep increases in out-of-pocket costs for brand drugs. Average Primary Cost Exposure, 2014-2017* (Commercial Copay Card Claims; All Brands) $200 $50 $100 $150 2015 Average Prescription Cost Sharing 2014 2017 2016 $0 Jan Mar May Jul Sep Nov Jan Mar May Jul Sep Nov Jan Mar May Jul Sep Nov Jan Mar May Jul Sep Copay Card Claims Non-copay Card Claims 91 4 Cost Sharing Trends Source: IQVIA14
Slide 96-

Manufacturer Cost Sharing Assistance Can Help Ease Patients’ Out-of-Pocket Costs Programs that do not count manufacturer cost sharing assistance toward a patient’s deductible or out-of-pocket maximum hurt the sickest patients, leaving them vulnerable to unexpected out-of-pocket costs as high as several thousands of dollars to continue taking their medicine. In 2017, just 0.4% of commercial claims were filled with a coupon for a brand medicine that had a generic equivalent. COUPON 92 4 Cost Sharing Trends Source: IQVIA15
Slide 97-

Biopharmaceutical Company Assistance Resources Help Patients With Much-Needed Financial Support Despite more Americans having insurance, many are facing high cost sharing that puts their ability to stay on a needed therapy at risk. Because of this, biopharmaceutical companies provide patient assistance in a variety of ways. Building off the work of the Partnership for Prescription Assistance, PhRMA built the Medicine Assistance Tool (MAT) in 2019 to provide patients, caregivers, and providers with a streamlined point of access for information that can help them make more informed health care decisions. MAT INCLUDES: A search engine to connect patients with medicine-speciﬁc ﬁnancial assistance programs Resources to help patients navigate their insurance coverage Links to websites providing cost information referenced in PhRMA member company direct-to-consumer television advertising 93 4 Cost Sharing Trends Source: PhRMA16
Slide 98-

Notes and Sources Avalere Health analysis of the US Department of Health and Human Services, Agency for Healthcare Research and Quality’s Medical Expenditure Panel Survey, 2016. https://meps.ahrq.gov/mepsweb. Accessed April 2019. Centers for Medicare and Medicaid Services (CMS), Office of the Actuary, National Health Statistics Group. National health care spending in 2016. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads /NHE-Presentation-Slides.pdf. Accessed May 2019. Claxton G, Levitt L, Rae M, et al.; Kaiser Family Foundation. Increases in cost-sharing payments continue to outpace wage growth. Peterson- Kaiser Health System Tracker. https://www.healthsystemtracker.org/brief/increases-in-cost-sharing-payments-have-far-outpaced-wage-growth. Published June 15, 2018. Accessed April 2019. PwC. Health & Well-being Touchstone Survey results. https://www.pwc.com/us/en/hr-management/publications/assets/pwc-touchstone -2017.pdf. Published June 2017. Accessed May 2019. Rae M, Levitt L, Claxton G, et al.; Kaiser Family Foundation. Patient cost-sharing in marketplace plans, 2016. http://kff.org/health-costs /issue-brief/patient-cost-sharing-in-marketplace-plans-2016. Published November 13, 2015. Accessed May 2019. Kaiser Family Foundation. 2018 Employer Health Benefits Survey. https://www.kff.org/health-costs/report/2018-employer-health-benefits -survey. Published October 2018. Accessed April 2019. Doshi JA, Li P, Ladage VP, et al. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions. Am J Manag Care. 2016;22(3):188-197. http://www.ajmc.com/journals/issue/2016/2016-vol22-n3/Impact-of-Cost-Sharing-on-Specialty-Drug -Utilization-and-Outcomes-A-Review-of-the-Evidence-and-Future-Directions. Accessed May 2019. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350. IQVIA. Patient affordability part one: the implications of changing benefit designs and high cost-sharing. https://www.iqvia.com/locations /united-states/patient-affordability-part-one. Published May 18, 2018. Accessed May 2019. IQVIA. Patient affordability part one: the implications of changing benefit designs and high cost-sharing. https://www.iqvia.com/locations /united-states/patient-affordability-part-one. Published May 18, 2018. Accessed May 2019. IQVIA. Patient affordability part two: implications for patient behavior and therapy consumption. https://www.iqvia.com/locations/united -states/patient-affordability-part-two. Published May 18, 2018. Accessed May 2019. IMS Institute for Healthcare Informatics. Emergence and impact of pharmacy deductibles: implications for patients in commercial health plans. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/emergence-and-impact-of-pharmacy-deductibles.pdf. Published September 2015. Accessed May 2019. 94 4 Cost Sharing Trends
Slide 99-

Notes and Sources IQVIA. Patient affordability part two: implications for patient behavior and therapy consumption. https://www.iqvia.com/locations/united-states /patient-affordability-part-two. Published May 18, 2018. Accessed May 2019. IQVIA. Patient affordability part three: the implications of co-pay cards. https://www.iqvia.com/locations/united-states/patient-affordability -part-three. Published May 18, 2018. Accessed May 2019. IQVIA. An evaluation of co-pay card utilization in brands after generic launch. https://www.iqvia.com/-/media/iqvia/pdfs/us-location-site/market -access/fact-sheet-evaluation-of-copay-card-utilization-post-loe.pdf. Published February 2018. Accessed May 2019. Pharmaceutical Research and Manufacturers of America (PhRMA). Medicine Assistance Tool website. https://www.mat.org. Accessed May 2019. 95 4 Cost Sharing Trends
Slide 100-

Photo placeholder 96
Slide 101-

SPENDING ON MEDICINES Understanding Medicine Costs in Context Prescription medicines represent a small share of national health spending, and government estimates project that medicines will remain a stable share of health spending through the next decade. In 7 of the past 10 years, spending on retail prescription medicines grew more slowly than total health care costs and is projected to grow just 3 percent to 6 percent annually over the next decade, in line with total health care spending. Rebates, discounts, and fees paid by brand manufacturers to the government, private payers, and supply chain entities increased to $166 billion in 2018. Brand medicine net price growth, which reflects these rebates and discounts, was less than inflation for the second year in a row. 5 97 97
Slide 102-

10% 12% 14% Annual Growth Rate 8% 6% 4% 2% 0% 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 Total Health Spending Growth Rate Prescription Medicine Spending Growth Rate* In 7 of the Last 10 Years, Retail Prescription Medicine Costs Grew More Slowly Than Total Health Care Costs Government actuaries project prescription medicine spending growth to remain between 3% and 6% annually through 2027, in line with overall health care spending growth.1 Prescription Medicine Spending Growth: 2009-20272 *Total net retail sales including brand medicines and generics 2014 saw 41 medicines approved by the FDA—including a number of transformative medicines for debilitating diseases—as well as 15.7 million Americans gaining coverage through the Affordable Care Act.3,4 98 5 Spending on Medicines Sources: PhRMA analysis of CMS data1,2; RAND Corporation3; FDA4
Slide 103-

Spending on All Prescription Medicines Is a Small Share of Total US Health Care Spending Other‡ Hospital Care PRESCRIPTION MEDICINES* Physician and Clinical Services Prescription medicines, whether picked up at a retail pharmacy or administered in a physician’s office or hospital, account for about 14% of total annual health care spending. Half of this total goes to brand manufacturers, with the rest going to generic manufacturers and the supply chain. Govt and Private Health Insurance Administration Nursing Home, Home Health, and Related 13% 14% 18% 8% 12% 31% US Health Care Spending 2017 4% Dental Services Brand Manufacturers 7% Generic Manufacturers 3% Supply Chain Entities† 4% TOTAL 14% *Breakout of prescription medicine spending based on analysis of 2015 data. †Supply chain entities include wholesalers, pharmacies, pharmacy benefit managers, and health care providers. ‡Other includes expenditures for Other Professional Services, Nondurable Medical Products, Durable Medical Equipment, Public Health Activity, Research, Structures, and Equipment. 99 5 Spending on Medicines Sources: PhRMA analysis of CMS data5; Altarum Institute6; Berkeley Research Group7
Slide 104-

Prescription Medicine Spending Contributed Less Than One-Tenth of Total Health Care Spending Growth in the Past Decade Cumulative Spending Growth Over 10 Years (in Billions), 2009-2018 $1,151.3 Dental and Other Professional Services Retail Prescription Medicines Physician Nursing Home, Health and Clinical Home Health, Insurance Services and Related Administrative Costs Hospital Care Total National Health Expenditures* $413.8 $230.3 $134.7 $126.1 $91.8 $64.7 *Total National Health Expenditures amount does not reflect listed categories. Not all categories are shown. 100 5 Spending on Medicines Sources: PhRMA analysis of CMS data8,9
Slide 105-

Prescription Medicines Are Expected to Account for a Stable Share of Total Health Care Expenditures Through the Next Decade *Retail prescription medicines are those filled at retail pharmacies or through mail service. Nonretail prescription medicines are those purchased through physicians’ offices, clinics, and hospitals and are typically administered to the patient by the provider. US Health Care Expenditures Attributable to Retail and Nonretail Prescription Medicines, 2010-2027* Actual10 Projected11 100% 20% 40% 60% 80% 0% 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 Other Health Care Spending Nonretail Retail 101 5 Spending on Medicines Sources: Altarum Institute10,11
Slide 106-

Cumulative Spending Growth for Other Health Care Will Be More Than Five Times That of Medicines Through the Next Decade Projected Cumulative Growth in Spending (in Billions), 2018-2027 $400 $350 $300 $250 $200 $150 $100 $50 $0 2022 2018 2019 2020 2021 Other Health Care 10-year cumulative increase: $2,101 billion 2023 2024 2025 2026 2027 Prescription Medicines (Retail and Nonretail) 10-year cumulative increase: $370 billion 102 5 Spending on Medicines Sources: PhRMA analysis of CMS data12; PhRMA analysis of Altarum Institute data13
Slide 107-

Projections of Future Medicine Spending Often Overestimate Actual Spending Actuaries at the Centers for Medicare and Medicaid Services (CMS) annually publish estimates of retail prescription medicine spending for the next 10 years. Looking back at projections made since 2000, estimates made 1 year prior to the publication of actual spending amounts overestimated retail medicine spending two-thirds of the time. Difference Between Projected and Actual Retail Medicine Spending (in Billions), 2001-2017 $15 $-3 $0 $3 $9 $12 $-6 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Sources: PhRMA analysis of CMS data14,15 -$3.0 -$3.6 -$1.7 -$2.5 -$2.7 -$0.4 $7.4 $6 $4.9 $12.1 $1.4 $3.8 $2.8 $12.0 $6.2 $1.0 $57.4B Total over- estimates $14.0B Total under- estimates $1.2 $4.6 103 5 Spending on Medicines
Slide 108-

Pharmacy Benefit Managers (PBMs) and Government Actuaries Report Slowing Growth in Medicine Spending Annual Growth in Net Retail Prescription Medicine Spending National Health CVS Health Express Scripts Expenditures *Projected 3.3%* 3.3% 0.4% 2015 5.0% 5.3% 8.9% 2018 104 5 Spending on Medicines Sources: CVS Health16,17; Express Scripts18,19; CMS20,21
Slide 109-

Competition From Generics and Biosimilars Is Expected to Reduce US Brand Sales by $105 Billion From 2019 to 2023 The savings from new generics and biosimilars in the coming years are expected to match the large-scale savings observed in recent years. Lower Brand Invoice Spending Due to Loss of Exclusivity (in Billions), 2014-2023 *Figures may not sum due to rounding. 2014-2018: $72 Billion* 2019-2023: $105 Billion Projected Actual 105 5 Spending on Medicines Source: IQVIA Institute22
Slide 110-

One-Third of Gross Spending for Medicines Is Rebated Back to Payers or Retained by the Supply Chain Manufacturers received $66 for every $100 of gross spending on medicines in 2018. Share of Total Rebates Received by Payer in 2018 Medicine List Price Rebates to Payers & Government Supply Chain Entities* Patient Assistance & Non-rebate Payments to Government** $100 -$23 -$5 -$6 Net Payment to Manufacturer $66 Based on overall market averages in 2018 Commercial Rebates 36% Medicaid Rebates 34% Medicare Rebates 30% *Supply chain entities include pharmacies, providers, wholesalers, and group purchasing organizations. **Includes FDA user fees, coverage gap discounts, 340B program discounts, and patient assistance. 106 5 Spending on Medicines Source: PhRMA analysis of Nephron Research data23
Slide 111-

Manufacturers’ Gross-to-Net Reductions Have More Than Doubled Since 2012 Rebates and discounts provided by manufacturers to government, private payers, and distributors totaled over $166 billion in 2018. Total Value of Pharmaceutical Manufacturers’ Gross-to-Net Reductions (in Billions), 2012-2018 2018 2017 2016 2015 2014 2013 2012 $74 $83 $102 $124 $139 $153 $166 GROSS-TO-NET REDUCTIONS are defined as “rebates, off-invoice discounts, copay assistance, price concessions, and other reductions like distribution fees, product returns, the 340B Drug Pricing Program, and more.” 107 5 Spending on Medicines Source: Drug Channels Institute24
Slide 112-

Patients Often Do Not Directly Benefit From Negotiated Rebates and Discounts Paid by Manufacturers Retains $2 Retains $25.25 SPENDS $408 Retains $53.75 Retains $239 SCOTT $400 purchase price $18 fee $0.25 fee tes/ $294 reba fees $384 purchase price Scott pays above the original purchase price of $400 (because he is still in the deductible phase within his health plan). $1.50 dispensing fee WHOLESALER PHARMACY PBM $240 rebates/fees $1 admin fee HEALTH PLAN/ PLAN SPONSOR Prices paid by wholesalers, pharmacies, pharmacy benefit managers (PBMs), and health plan sponsors all vary and are determined by negotiations between stakeholders, each with varying degrees of negotiating power. Flow of Payment for a $400 Insulin Prescription (Patient is in Deductible Phase) MANUFACTURER Retains $88 This graphic is illustrative of a hypothetical product with a wholesale acquisition cost (WAC) of $400 and an average wholesale price (AWP) of $480. It is not intended to represent every ﬁnancial relationship in the marketplace. The payment amounts do not add up to $400 due to markups and discounts along the supply chain. Source: PhRMA25 $408 purchase price 108 5 Spending on Medicines
Slide 113-

Growth in Prescription Medicine Prices Has Been in Line With Other Health Care Prices Average Price Levels, Selected Goods and Services, 2000-2018 90 110 130 150 170 190 250 230 210 270 290 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 100 Hospital and Related Services Medical Care Prescription Medicines Consumer Price Index— Urban, All Items Consumer Price Index 109 5 Spending on Medicines Source: PhRMA analysis of Bureau of Labor Statistics data26
Slide 114-

*Includes protected brand medicines only (ie, brand medicines without generic versions available in the year indicated). **Estimated net price growth reflects impact of off-invoice rebates and discounts provided by manufacturers. 0% 2% 4% 6% 8% 10% 12% 14% 2018 2017 2015 2016 Estimated Net Price** 2014 2013 2012 2011 9.3% 10.0% 11.3% Rebates and Other Discounts Offset Virtually All Growth in Medicine Prices in 2018 Commonly reported invoice (or list) prices are higher than what payers ultimately pay for medicines. Average Price Growth for Brand Medicines, 2011-2018* 16% 13.5% 9.0% 8.7% 9.1% 4.7% 4.3% 3.2% 11.9% 2.4% 6.9% 1.9% 5.5% 0.3% Invoice Price 110 5 Spending on Medicines Source: IQVIA Institute27
Slide 115-

Nine out of Every Ten US Prescriptions Are Filled With Generics *Generic share includes generics and branded generics. “Other” category from IMS National Prescription Audit™ not included in calculation. Generic Share of Prescriptions Filled, 1984-2018* 2018 2014 2008 2002 1996 1990 1984 19% 33% 43% 52% 72% 88% 90% 111 5 Spending on Medicines Sources: IQVIA Institute28; Drug Channels Institute29
Slide 116-

*Each price represents the average annual price for 30 pills of the most commonly dispensed form and strength. “Then” price represents the average price in the year prior to generic entry. “Now” price represents the average price in December 2017. The US Prescription Medicine Lifecycle Promotes Innovation and Affordability Hypertension Blood Thinner 2010 BRAND NAME THEN MEDICINE* % CHANGE GENERIC NOW VS. Bipolar Disorder Biopharmaceutical companies invest in pioneering research to bring new medicines to patients, and over time those medicines become available as lower-cost generic copies. THEN & NOW How Prescription Medicine Prices Fall Signiﬁcantly Over Time 112 5 Spending on Medicines Source: IQVIA Institute30
Slide 117-

Spending on Cancer Medicines Represents Less Than 2% of Overall Health Care Spending *Cancer medicine spending reflects invoice spending, which does not account for rebates and discounts. **Projected Cancer Medicines as a Portion of Total US Health Care Spending, 2018 Cancer Medicines $58.4 Billion31* TO TA L Health Care Spendin g $3.6 Trillion32** 113 5 Spending on Medicines Sources: IQVIA Institute31; CMS32
Slide 118-

Notes and Sources Centers for Medicare & Medicaid Services (CMS). National health expenditure projections 2018-2027: forecast summary. https://www.cms.gov /Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ForecastSummary.pdf. Published February 2019. Accessed May 2019. Centers for Medicare & Medicaid Services (CMS). National health expenditure data. https://www.cms.gov/Research-Statistics-Data-and -Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/index.html. Accessed May 2019. Carman KG; RAND Corporation. Health coverage grows under Affordable Care Act. http://www.rand.org/news/press/2015/05/06.html. Published May 6, 2015. Accessed May 2017. Food and Drug Administration (FDA). New drugs at FDA: CDER’s new molecular entities and new therapeutic biological products. https://www .fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products. Last updated February 2, 2018. Accessed May 2018. Centers for Medicare & Medicaid Services (CMS). National health expenditures 2017 highlights. https://www.cms.gov/Research-Statistics-Data -and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/highlights.pdf. Accessed May 2019. Roehrig C; Altarum Institute. A ten year projection of the prescription drug share of national health expenditures, including non-retail. https:// altarum.org/sites/default/files/uploaded-publication-files/Non-Retail%20Rx%20Forecast%20Data%20Brief%20with%20Addendum%20 May%202017.pdf. Published October 2014. Updated May 2017. Accessed May 2018. Vandervelde A, Blalock E; Berkeley Research Group. The pharmaceutical supply chain: gross drug expenditures realized by stakeholders. http:// www.thinkbrg.com/media/publication/863_Vandervelde_PhRMA-January-2017_WEB-FINAL.pdf. Published 2017. Accessed May 2017. Centers for Medicare & Medicaid Services (CMS). National health expenditure data. https://www.cms.gov/Research-Statistics-Data-and -Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/index.html. Accessed May 2019. Centers for Medicare & Medicaid Services (CMS). National health expenditure projections 2018-2027: forecast summary. https://www.cms.gov /Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ForecastSummary.pdf. Published February 2019. Accessed May 2019. Roehrig C; Altarum Institute. Projections of the prescription drug share of national health expenditures including non-retail. https://altarum.org /sites/all/libraries/documents/Projections_of_the_Prescription_Drug_Share_of_National_Health_Expenditures_June_2018.pdf. Published May 2018. Accessed June 2018. Roehrig C; Altarum Institute. Projections of the prescription drug share of national health expenditures including non-retail. https://altarum.org /publications/projections-prescription-drug-share-national-health-expenditures-including-non-retail-0. Published June 2019. Accessed June 2019. 114 5 Spending on Medicines
Slide 119-

Notes and Sources Centers for Medicare & Medicaid Services (CMS). National health expenditure data. https://www.cms.gov/Research-Statistics-Data-and -Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/index.html. Accessed May 2019. Roehrig C; Altarum Institute. Projections of the prescription drug share of national health expenditures including non-retail. https://altarum.org /publications/projections-prescription-drug-share-national-health-expenditures-including-non-retail-0. Published June 2019. Accessed June 2019. Centers for Medicare & Medicaid Services (CMS). National health expenditure data. https://www.cms.gov/Research-Statistics-Data-and -Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/index.html. Accessed May 2019. Centers for Medicare & Medicaid Services (CMS). National health expenditure projections 2018-2027: forecast summary. https://www.cms.gov /Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ForecastSummary.pdf. Published February 2019. Accessed May 2019. CVS Health. 2015 drug trend: tackling rising drug costs. https://cvshealth.com/thought-leadership/cvs-health-research-institute/2015-drug -trend-tackling-rising-drug-costs. Published February 22, 2016. Accessed April 2019. CVS Health. 2018 drug trend report. https://payorsolutions.cvshealth.com/insights/2018-drug-trend-report. Published April 11, 2019. Accessed April 2019. Express Scripts. 2015 drug trend report. http://lab.express-scripts.com/lab/drug-trend-report/previous-reports. Published March 2016. Accessed April 2019. Express Scripts. 2018 drug trend report. http://lab.express-scripts.com/lab/drug-trend-report/2018-drug-trend-report. Accessed April 2019. Centers for Medicare & Medicaid Services (CMS). National health expenditure data. Historical. NHE tables. https://www.cms.gov/Research -Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html. Accessed April 2019. Centers for Medicare & Medicaid Services (CMS). National health expenditure projections 2018-2027: forecast summary. https://www.cms.gov /Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ForecastSummary.pdf. Published February 2019. Accessed May 2019. IQVIA Institute for Human Data Science. Medicine use and spending in the U.S.: a review of 2018 and outlook to 2023. https://www.iqvia.com /institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023. Published May 2019. Accessed May 2019. Nephron Research. Presentation at the Operationalizing a World Without Rebates Forum; March 21, 2019; Washington, DC. 115 5 Spending on Medicines
Slide 120-

Notes and Sources Fein AJ; Drug Channels Institute. The 2019 economic report on U.S. pharmacies and pharmacy benefit managers. https://www.drugchannels .net/2019/03/new-2019-economic-report-on-us.html. Published March 2019. Accessed March 2019. Pharmaceutical Research and Manufacturers of America (PhRMA). Follow the dollar: understanding how the pharmaceutical distribution and payment system shapes the prices of brand medicines. http://phrma-docs.phrma.org/files/dmfile/Follow-the-Dollar-Report.pdf. Published November 2017. Accessed May 2017. US Bureau of Labor Statistics. CPI-all urban consumers (current series). https://data.bls.gov/PDQWeb/cu. Accessed May 2019. IQVIA Institute for Human Data Science. Medicine use and spending in the U.S.: a review of 2018 and outlook to 2023. https://www.iqvia.com /institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023. Published May 2019. Accessed May 2019. IQVIA Institute for Human Data Science. Medicine use and spending in the U.S.: a review of 2017 and outlook to 2022. https://www.iqvia.com /institute/reports/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022. Published April 2018. Accessed April 2018. Fein AJ; Drug Channels Institute. The 2019 economic report on U.S. pharmacies and pharmacy benefit managers. https://www.drugchannels .net/2019/03/new-2019-economic-report-on-us.html. Published March 2019. Accessed March 2019. IQVIA Institute for Human Data Science analysis for PhRMA. May 2018. IQVIA Institute for Human Data Science. Medicine use and spending in the U.S.: a review of 2018 and outlook to 2023. https://www.iqvia.com /institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023. Published May 2019. Accessed May 2019. Centers for Medicare & Medicaid Services (CMS). National health expenditure projections 2018-2027: forecast summary. https://www.cms.gov /Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ForecastSummary.pdf. Published February 2019. Accessed May 2019. 116 5 Spending on Medicines
Slide 121-

Photo placeholder 117
Slide 122-

Photo placeholder 118
Slide 123-

OUTCOMES AND SAVINGS Overcoming Gaps in Treatment, Improving Outcomes, and Reducing Costs Through Better Use of Medicines Undertreatment of complex and chronic conditions as well as suboptimal use of prescribed medicines are significant public health problems, costing the US economy hundreds of billions of dollars each year. Medicines help patients live healthier lives and reduce the need for costly health care services such as emergency department visits, hospital stays, surgeries, and long-term care. An ever-growing body of evidence demonstrates that improved use of prescribed medicines can result in better health outcomes, lower costs for other health care services, and increased worker productivity. 6 119 119
Slide 124-

The Human and Economic Costs of Chronic Disease More than 1 million lives could be saved annually through better treatment and prevention of chronic disease. $8,600 mean annual cost per person in the US AMERICANS 191 million have at least one 75 million have multiple Costs of CHRONIC DISEASE 5% of the population accounts for 50%of US health care spending2 $42 trillion estimated cost 2016-2030 120 6 Outcomes and Savings Sources: IHS1; Agency for Healthcare Research and Quality2
Slide 125-

*Treatment includes blood sugar control (medicines, diet, and exercise) and testing to prevent complications. Sources: American Diabetes Association3; IHS Life Sciences analysis of CDC data4 30 million Americans have DIABETES 7 million are UNDIAGNOSED 19 million are TREA TED 4 million are UNTREATED 8 million are SUCCESSFULLY T R E A T E D 11 million are UNSUCCESSFULLY T R E A T E D 8 million have CONTROLLED D I A B E T E S 22 million have UNCONTROLLED D I A B E T E S 23 million are DIAGNOSED Diabetes: An Example of Underdiagnosis and Undertreatment Uncontrolled diabetes can lead to kidney failure, amputation, blindness, and stroke. Care for people with diagnosed diabetes accounts for 1 in 4 health care dollars in the United States.3 PREVALENCE DIAGNOSIS TREATMENT* CONTROL 121 6 Outcomes and Savings
Slide 126-

Potential Savings From Better Use of Medicines Better use of medicines could eliminate up to $213 billion in US health care costs annually, which represents 8% of the nation’s health care spending. Sources of Avoidable Annual US Health Care Costs, 2012 (in Billions) *Category includes medication errors ($20 billion) and mismanaged polypharmacy ($1 billion). **Category includes untimely medicine use ($40 billion), inappropriate antibiotic use ($35 billion), and suboptimal generic use ($12 billion). $0 $50 $100 $150 $200 $250 Total Avoidable Costs Suboptimal Prescribing** Medication Errors* Nonadherence $105 $21 $87 $213 122 6 Outcomes and Savings Source: IMS Institute for Healthcare Informatics5
Slide 127-

Lowering Cost Sharing for Seniors at the Pharmacy Counter Can Generate Medicare Savings Sharing a portion of negotiated manufacturer rebates directly with patients could improve medicine adherence and result in savings for seniors and Medicare in Part D. BENEFITS OF SHARING NEGOTIATED REBATES: Lower beneﬁciary out- of-pocket spend by $350 per year Save Medicare nearly $1,000 per year for every senior taking diabetes medicine Reduce total health care spending by approximately $20B over 10 years 123 6 Outcomes and Savings Source: IHS Markit6
Slide 128-

Better Use of Medicines Yields Significant Health Gains by Avoiding the Need for Other Medical Services Due to a growing body of evidence, in 2012 the Congressional Budget Office (CBO) began recognizing reductions in other medical expenditures associated with an increased use of prescription medicines in Medicare. Since the CBO announcement, the evidence has continued to develop, broadening the potential for cost offsets in the health care system. $ CHRONIC DISEASES Medicare savings due to better use of medicines may be 3 to 6 times greater than estimated by the CBO for seniors with common chronic conditions, including heart failure, diabetes, and hypertension.8 MEDICAID Increased use of medicines is associated with reductions in Medicaid expenditures from avoided use of inpatient and outpatient services.9,10 Pharmaceuticals have the effect of improving or maintaining an individual’s health . . . adhering to a drug regimen for a chronic condition such as diabetes or high blood pressure may prevent complications . . . taking the medication may also avert hospital admissions and thus reduce the use of medical services.” — CBO7 124 6 Outcomes and Savings Sources: CBO7; Roebuck MC8; Roebuck MC et al.9,10
Slide 129-

Improved Medicine Use Can Lead to Savings in Medicare Between 20% and 40% of Medicare beneficiaries with common chronic diseases are not adherent to their medicines. Billions of dollars in cost savings from avoided hospital stays can result from improved adherence. $5,170 $5,824 Annual Savings per Person From Better Adherence $1,847 $7,893 Diabetes Hyper- Heart Hypertension lipidemia Failure HYPERLIPIDEMIA $5.1B 5.2M cost savings avoidable hospital inpatient days HYPERTENSION avoidable hospital inpatient days $13.7B 7.3M cost savings HEART FAILURE $5.6B 4.2M cost savings avoidable hospital inpatient days DIABETES cost savings $4.5B 2.9M avoidable hospital inpatient days Outcomes With Improved Adherence 125 6 Outcomes and Savings Source: Lloyd JT et al.11
Slide 130-

Better Adherence Generates Savings in Medicaid Optimal adherence to medicines for a range of chronic conditions leads to reductions in hospitalizations for many patients enrolled in Medicaid. Reductions in Hospitalizations Due to Medication Adherence* Economic impact of nonadherence on Asthma/COPD Diabetes Hypertension Schizophrenia/ Bipolar Disorder Congestive Heart Failure *Results apply to Medicaid populations that are not blind or disabled. 126 6 Outcomes and Savings Source: Roebuck MC et al.12
Slide 131-

Improving Access to Treatment Could Reduce the Clinical and Economic Impact of Addiction The economic impact of the opioid crisis in the United States was estimated to be $504 billion in 2015.13 Medication-assisted treatment (MAT) is an evidence-based approach for the treatment of opioid use disorder that pairs behavioral therapy with medicines that block the effects of opioids and/or mitigate the symptoms of opioid withdrawal. 127 6 Outcomes and Savings Sources: Hagemeier, NE13; IHS Markit14
Slide 132-

Recent Studies Show Significant Value From Better Use of Medicines Patients with a range of diseases could offset health care spending by exercising better adherence. PARKINSON’S DISEASE Health care savings of up to $6,300 in fewer than 2 years can be achieved among patients with Parkinson’s who continually stay on therapy.15 CYSTIC FIBROSIS Among children with cystic fibrosis, poor medication adherence is associated with more hospitalizations and emergency department visits and an increase of more than $14,000 in same-year medical costs compared with children who are highly adherent.17 LUPUS Nonadherence among children on Medicaid who are diagnosed with lupus is associated with a 55% increase in emergency department use and a nearly 40% increase in hospitalizations.18 MULTIPLE SCLEROSIS Initiation of therapy is associated with reductions of up to $5,700 in medical costs, driven by decreased use of outpatient services and inpatient hospital stays.16 128 6 Outcomes and Savings Sources: Wei YJ et al.15; Nicholas J et al.16; Quittner AL et al.17; Feldman CH et al.18
Slide 133-

0% 10% 20% 30% 40% 50% Average Increase, all Diseases Gastrointestinal Infectious Hepatitis C Disease Areas With Innovative Medicines Musculoskeletal 27% 15% 43% 167% 30% Percent Increase in Worker Productivity Due to Innovative Medicines 200% Innovative Medicines Improve Patients’ Ability to Work New drugs increase worker productivity by 4.8 million work days and add $221 billion in wages per year. 129 6 Outcomes and Savings Source: Chen AJ et al.19
Slide 134-

Notes and Sources IHS. Burden of chronic illnesses in the US: technical overview. http://www.fightchronicdisease.org/sites/default/files/IHS_Technical_Report.pdf. Published May 2016. Accessed May 2017. Cohen SB; Agency for Healthcare Research and Quality. The concentration and persistence in the level of health expenditures over time: estimates for the U.S. population, 2012-2013. Statistical Brief 481. http://meps.ahrq.gov/mepsweb/data_files/publications/st481/stat481.pdf. Published September 2015. Accessed May 2017. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. http://care.diabetesjournals.org/content/early/2018/03/20 /dci18-0007. Published March 2018. Accessed May 2018. IHS Life Sciences analysis of Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, data. National Health and Nutrition Examination Survey, 2013-2014. https://wwwn.cdc.gov/nchs/nhanes/ContinuousNhanes/Default.aspx?BeginYear=2013. Accessed May 2017. IMS Institute for Healthcare Informatics. Avoidable costs in U.S. healthcare: the $200 billion opportunity from using medicines more responsibly. https://www.drugstorenews.com/wp-content/uploads/2013/06/Avoidable-Costs-in-Healthcare.pdf. Published June 2013. Accessed May 2017. Su W, Dall T; IHS Markit. Passing a portion of negotiated rebates through to seniors with diabetes can improve adherence and generate savings in Medicare. https://cdn.ihs.com/www/pdf/IHSM-RebateSharingReport-10May2018.pdf. Published May 2018. Accessed May 2019. Congressional Budget Office (CBO). Offsetting effects of prescription drug use on Medicare’s spending for medical services. https://www.cbo .gov/publication/43741. Published November 2012. Accessed May 2017. Roebuck MC. Medical cost offsets from prescription drug utilization among Medicare beneficiaries [commentary]. J Manag Care Spec Pharm. 2014;20(10):994-995. Roebuck MC, Dougherty JS, Kaestner R, et al. Increased use of prescription drugs reduces medical costs in Medicaid populations. Health Aff (Millwood). 2015;34(9):1586-1593. Roebuck MC, Kaestner RJ, Dougherty JS. Impact of medication adherence on health services utilization in Medicaid. Med Care. 2018;56(3): 266-273. Lloyd JT, Maresh S, Powers CA, et al. How much does medication nonadherence cost the Medicare fee-for-service program? Med Care. 2019; 57(3):218-224. Roebuck MC, Kaestner RJ, Dougherty JS. Impact of medication adherence on health services utilization in Medicaid. Med Care. 2018;56(3): 266-273. 130 6 Outcomes and Savings
Slide 135-

Notes and Sources Hagemeier NE. Introduction to the opioid epidemic: the economic burden on the healthcare system and impact on quality of life. Am J Manag Care. 2018;24(suppl 10):S200-S206. Chen F, Semilla A, Su W; IHS Markit. Improving access to medication-assisted treatment for opioid use disorder among the commercially-insured US population. https://cdn.ihs.com/www/pdf/1218/IHSMarkit-Impact-Improving-Access-Opioid-Addiction.pdf. Published November 2018. Accessed April 2019. Wei YJ, Palumbo FB, Simoni-Wastila L, et al. Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population. Value Health. 2014;17(2):196-204. Nicholas J, Boster A, Wu N, et al. Comparison of disease-modifying therapies for the management of multiple sclerosis: analysis of healthcare resource utilization and relapse rates from US insurance claims data. Pharmacoecon Open. 2018;2(1):31-41. Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146(1):142-151. Feldman CH, Yazdany J, Guan H, et al. Medication nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res. (Hoboken). 2015;67(12):1712-1721. Chen AJ, Goldman DP. Productivity benefits of medical care: evidence from US-based randomized clinical trials [published online March 9, 2018]. Value Health. 2018;21(8):905-910. doi:10.1016/j.jval.2018.01.009 131 6 Outcomes and Savings
Slide 136-

Photo placeholder 132
Slide 137-

ECONOMIC IMPACT Sustaining and Growing State and Local Economies America’s biopharmaceutical industry is the foundation for one of the country’s most dynamic innovation and business ecosystems. The industry is among the most research and development (R&D)-intensive in the United States, accounting for 1 out of every 6 dollars spent on domestic R&D by US businesses. The industry’s large-scale research and manufacturing footprint, along with its attendant supply chain, supports high-quality jobs in communities across the United States. More biopharmaceutical venture capital is invested in startups in the United States than anywhere else in the world, providing an ongoing source of highly skilled jobs aimed at making advances in biopharmaceutical science. However, US leadership in innovation is facing increasing challenges from emerging global competitors seeking to attract and grow a biopharmaceutical presence in their own countries. 7 133 133
Slide 138-

Scientiﬁc R&D Services Aerospace Computer Systems Design Automobiles Software Pharmaceuticals & Medicines 18% 10% 6% 4% 4% 1% The Biopharmaceutical Industry Is the Single Largest Funder of Business R&D in the United States The biopharmaceutical industry accounts for the single largest share of all self-funded R&D, representing 1 out of every 6 dollars (18%) spent on domestic R&D by US businesses. Furthermore, US industry is also the largest global funder of biopharmaceutical R&D, accounting for about half of all R&D investments worldwide. Share of Total US Business R&D by Industry, 2016* *The remaining 57% share of business R&D spending is conducted by other industries, including subsectors of the machinery sector, the computer and electronic products sector, and the electrical equipment, appliance, and components sector. 134 7 Economic Impact Source: PhRMA analysis of National Science Foundation data1
Slide 139-

Petroleum & Coal Semiconductor Pharmaceuticals & Medicines Communications Equipment 25.3% 20.5% 15.2% 0.2% 21.5% The US Biopharmaceutical Sector Is Among the Biggest Investors in R&D Relative to Sales Biopharmaceutical investments in R&D, as a percentage of sales, are more than 6 times the average for all manufacturing industries, making the sector one of the most R&D-intensive industries. R&D as a Percentage of Sales by Industry, 2001-2015 135 7 Economic Impact Source: NDP Analytics2
Slide 140-

The Biopharmaceutical Industry Invests More R&D Dollars per Employee Than Any Other Industry On a per employee basis, biopharmaceutical companies invest 12 times more in R&D than the average for manufacturing industries overall. R&D Expenditures per Employee by Manufacturing Sector and Industry, 2001-2015 136 7 Economic Impact Source: NDP Analytics3
Slide 141-

Navigational Equipment Aerospace Automobiles Semiconductors Biopharmaceuticals 11% 8% 7% 11% One out of every eight R&D workers in the nation’s manufacturing industries is employed by the biopharmaceutical industry. Selected Manufacturing Industries’ Share of Total R&D Workers, 2015* 13% *All other manufacturing sectors account for the remaining 50% of the R&D workforce. The Biopharmaceutical Industry Employs the Largest Share of All Manufacturing R&D Workers 137 7 Economic Impact Source: PhRMA analysis of National Science Foundation data4
Slide 142-

The Economic Reach of the US Biopharmaceutical Industry Every biopharmaceutical sector job supports a total of five jobs across the economy. indirect jobs (Vendors and Suppliers) 811,000 direct jobs (Innovative Biopharmaceutical Industry) 1,422,000 4,039,000 TOTAL JOBS 1,806,000 induced jobs (Additional Private Economic Activity) The biopharmaceutical industry supported more than 4 million jobs across the US economy in 2017. Source: TEConomy Partners5 138 7 Economic Impact
Slide 143-

The US Biopharmaceutical Sector Produces High-Quality Jobs Across an Array of Fields One-third of the jobs in the biopharmaceutical sector are in key STEM (Science, Technology, Engineering, and Mathematics) occupations, a far higher share than in the private sector as a whole. Percentage of Jobs in Sector by Occupation, 2017* *Column percentages may not add up to 100% due to rounding. †Indicates a STEM occupation. ‡Other occupations include health care practitioners/techs (2.8% of biopharma industry jobs); installation/maintenance/repair (2.5%); arts/design/entertainment/sports/media (0.9%); building & grounds cleaning/maint (0.6%); legal (0.4%); health care support (0.4%); construction/extraction (0.3%); educ/training/library science (0.3%); protective services (0.2%); community/ social services (0.2%); personal care & service (0.1%); farming/fishing/forestry (0.1%); and food prep/serving (0.1%). 139 7 Economic Impact Source: TEConomy Partners6
Slide 144-

US Biopharmaceutical Exports Have Grown Biopharmaceutical exports have nearly tripled since 2002, accounting for about 4% of all US exports in 2018. US Biopharmaceutical Goods Exports (in Billions)8 — International Trade Administration7 Pharmaceuticals rank as one of the top exporting sectors for IP-intensive industries in the United States.” 2018 2014 2010 2006 2002 $18.7 $32.2 $46.6 $50.3 $54.7 140 7 Economic Impact Sources: ITA7; PhRMA analysis of US Census Bureau data8
Slide 145-

The Biopharmaceutical Sector’s Extensive US Manufacturing Footprint 125 130 82 57 53 47 40 38 34 23 25 31 19 18 20 16 11 8 7 7 7 6 6 5 21 5 4 4 2 2 1 6 1 1 30 26 15 13 Puerto Rico 3 3 7 65 9 5 71 Approximately 1,100 manufacturing plants involved in the production of human-use medicines are located in 45 US states and Puerto Rico. Biopharmaceutical companies are building the plants to make cutting-edge therapies of the future in the United States. Biopharmaceutical Manufacturing Facilities by State/Territory (January 2019)9,10 8 1 141 7 Economic Impact Sources: NDP Analytics9; Hargreaves B10
Slide 146-

*Estimates reflect only those activities occurring at clinical trial sites and exclude more centralized cross-site functions such as coordination and data analysis. Also excluded are nonclinical R&D activities such as basic and preclinical research and the significant economic contribution from non-R&D activities of the industry such as manufacturing and distribution. In 2017, the biopharmaceutical industry sponsored more than 4,500 clinical trials of medicines in the United States, involving 920,000 participants and supporting $42 billion in economic activity across all 50 states, the District of Columbia, and Puerto Rico.* Estimated Total Economic Impact of Industry-Sponsored Clinical Trials Activity Across the US, 2017 Industry-Sponsored Clinical Trials Contribute Significant Value to the Communities in Which They Are Located Output Total Impact $2,500+ million $1,000 million to $2,499 million $100 million to $999 million Up to $99 million 142 7 Economic Impact Source: TEConomy Partners11
Slide 147-

States Are Increasingly Targeting the Biopharmaceutical Industry in Their Economic Development Plans Recognizing the broad economic impact of the biopharmaceutical industry, states across the country are adopting a range of policies and programs to attract and grow the industry within their borders. Common policies and programs that states are pursuing include: Adopting comprehensive, targeted strategies for life science industry development Building research capacity and infrastructure Building advanced manufacturing capabilities Advancing the STEM talent pipeline Accelerating innovation through entrepreneurial development programs Increasing the availability of ﬁnancial capital for life science development Establishing economic incentives for life science innovation 143 7 Economic Impact Source: TEConomy Partners12
Slide 148-

*Percentages may not add up to 100% due to rounding. **Asia includes India, Malaysia, South Korea, and others. The United States Leads in Biopharmaceutical Intellectual Property More than half of the intellectual property related to new medicines was created in the United States. US Patents Granted in Pharmaceuticals by Region/Country of Inventor, 2016* European Union, 19.5% All Others, 9.1% United States, 56.9% Asia,** 6.7% Japan, 5.2% China, 2.6% 144 7 Economic Impact Source: PhRMA analysis of National Science Foundation data13
Slide 149-

The United States Leads in Biopharmaceutical Venture Capital Investment Almost three-quarters of worldwide venture capital investments in biopharmaceutical startups are made in the United States. Biopharmaceutical Venture Capital Investment by Region/Country, 2018* All Others, 3.5% United States, 72.1% Europe, 13.4% China, 11.1% *Percentages may not add up to 100% due to rounding. 145 7 Economic Impact Source: TEConomy analysis for PhRMA14
Slide 150-

Biopharmaceutical Venture Capital Provides Tremendous Resources for Startup Company Financing Between 2000 and 2017, venture capitalists invested over $95 billion in more than 8,000 deals helping to start up over 3,300 biopharmaceutical companies across the United States. NORTHEAST $38.1B invested 2,616 deals 1,056 startups SOUTH $10.4B invested 1,574 deals 663 startups MIDWEST $3.6B invested 736 deals 345 startups WEST $43.1B invested 3,239 deals 1,294 startups 146 7 Economic Impact Source: PhRMA analysis of PitchBook Venture Investment database15
Slide 151-

The Biopharmaceutical Industry Supports a Broader Ecosystem Through Corporate Venture Capital Corporate venture capital (CVC) from biopharmaceutical companies and others plays an increasingly important role in financing emerging biopharmaceutical companies, now accounting for over half of VC investment in the sector. US CVC Investment in Biopharmaceutical Startups, 2008-2018 2018 2017 2013 2014 2015 2016 CVC % Share of Total VC Invested 2010 2011 2012 US CVC Invested (Billions) 2009 2008 $1.50 $1.87 $1.28 $1.72 $1.86 $2.49 $3.40 $5.12 $4.42 $5.84 $10.20 30.6% 38.4% 27.9% 35.4% 37.3% 41.7% 45.3% 49.0% 49.1% 49.3% 58.7% 147 7 Economic Impact Source: 4Q 2018 Pitchbook-NVCA Venture Monitor16
Slide 152-

The Biopharmaceutical Industry Is Reducing Its Impact on the Environment Biopharmaceutical companies are pioneers in green chemistry and are committed to finding creative and innovative ways, including the following, to reduce waste, conserve energy, and adopt other more environmentally friendly processes. Implementing manufacturing methods that replace many solvents with safer alternatives Constructing facilities that are LEED-certiﬁed (Leadership in Energy and Environmental Design) Expanding use of biocatalyzed processes, which are shorter, produce less waste, and reduce environmental impact Adopting new manufacturing processes to reduce emissions and energy use Adapting single-use production systems to minimize environmental impact Setting limits on wastewater discharges to reduce environmental impact of manufacturing discharges18 Technology GREEN Chemistry 148 7 Economic Impact Sources: Deloitte17; IFPMA18
Slide 153-

The Biopharmaceutical Industry Is Advancing STEM Education in the United States The STEM workforce accounts for more than 50% of the nation’s sustained economic growth. From 2008 to 2012, PhRMA member companies and their foundations supported more than 90 STEM education programs across the United States, impacting more than 1.6 million students and 17,500 teachers. PhRMA member company and foundation contributions to STEM education in the United States include: STEM Number of employee volunteers 4,500 Number of individual STEM-related grants awarded 600 Number of employee hours volunteered 27,000 Total STEM education program funding provided $100M Percentage of industry-sponsored STEM programs focused on K-12 85% 149 7 Economic Impact Source: Battelle Technology Partnership Practice19
Slide 154-

0 Other Nations Are Challenging US Leadership in Biopharmaceutical Innovation Emerging economies are exceeding US performance on key measures related to a robust biopharmaceutical environment. The United States is now facing increasing competition to attract and grow a biopharmaceutical presence, not just from developed countries, but also from emerging nations, such as Brazil, China, and Singapore, that are laying the groundwork for future growth.” — TEConomy Partners20 D 150 7 Economic Impact Sources: TEConomy Partners20,21
Slide 155-

Industry analysts have consistently identiﬁed 3 policy areas as critical for the US biopharmaceutical industry to remain an engine of economic growth and innovation: Fostering Growth of the US Biopharmaceutical Industry Depends on Policies That Support R&D Investment The capability to innovate is fast becoming the most important determinant of economic growth and a nation’s ability to compete and prosper in the 21st century global knowledge-based economy.” — Battelle Technology Partnership Practice22 151 7 Economic Impact Sources: Battelle Technology Partnership Practice, PhRMA22; Deloitte23
Slide 156-

Notes and Sources Wolfe RM; National Science Foundation, National Center for Science and Engineering Statistics. Businesses spent $375 billion on R&D performance in the United States in 2016. InfoBriefs. NSF 18-312. https://www.nsf.gov/statistics/2018/nsf18312/nsf18312.pdf. Published September 2018. Accessed April 2019. NDP Analytics. IP-intensive manufacturing industries: driving US economic growth. http://www.ndpanalytics.com/s/IP-Report-2017.pdf. Published September 2017. Accessed April 2019. NDP Analytics. IP-intensive manufacturing industries: driving US economic growth. http://www.ndpanalytics.com/s/IP-Report-2017.pdf. Published September 2017. Accessed April 2019. National Science Foundation, National Center for Science and Engineering Statistics. Table 50: worldwide, domestic, and foreign total and R&D employment, by industry and company size: 2015. https://ncses.nsf.gov/pubs/nsf18313/#data-tables&. Published August 30, 2018. Accessed April 2019. TEConomy Partners; for PhRMA. The Economic Impact of the US Biopharmaceutical Industry 2017: National and State Estimates. Columbus, OH: TEConomy Partners. In press. TEConomy Partners; for PhRMA. The Economic Impact of the US Biopharmaceutical Industry 2017: National and State Estimates. Columbus, OH: TEConomy Partners. In press. US Department of Commerce, International Trade Administration (ITA). 2016 Top Markets Report: Pharmaceuticals. Executive summary. http:// trade.gov/topmarkets/pdf/Pharmaceuticals_Executive_Summary.pdf. Published May 2016. Accessed June 2017. US Census Bureau. U.S. international trade data. US Census Bureau website. https://www.census.gov/foreign-trade/data/index.html. Accessed March 2019. NDP Analytics; for PhRMA. Analysis of the US Food and Drug Administration’s Drug Establishments Current Registration Site. April 2019. Hargreaves B. GSK ramps up Shingrix production with $100m investment. InPharma Technologist website. https://www.in-pharmatechnologist .com/Article/2019/04/25/GSK-ramps-up-investment-into-Shingrix-production. Published April 25, 2019. Accessed April 2019. TEConomy Partners; for PhRMA. Biopharmaceutical industry-sponsored clinical trials: growing state economies. http://phrma-docs.phrma.org /files/dmfile/TEConomy_PhRMA-Clinical-Trials-Impacts.pdf. Published April 2019. Accessed May 2019. TEConomy Partners; for PhRMA. Driving Innovation and Economic Growth for the 21st Century: State Efforts to Attract and Grow the Biopharmaceutical Industry. Columbus, OH: TEConomy Partners; December 2016. 152 7 Economic Impact
Slide 157-

Notes and Sources National Science Foundation, National Science Board. Science and Engineering Indicators 2018. Chapter 8 Appendix Table 8-13: USPTO patents granted in pharmaceuticals, by region, country, or economy: 2000–16. https://www.nsf.gov/statistics/2018/nsb20181/data/appendix. Published 2018. Accessed April 2019. TEConomy; for PhRMA. Analysis of Pitchbook data. https://pitchbook.com. April 2019. Pharmaceutical Research and Manufacturers of America (PhRMA) analysis of PitchBook Venture Investment database. https://pitchbook.com. Accessed December 2018. 4Q 2018 Pitchbook-NVCA Venture Monitor. https://pitchbook.com/news/reports/4q-2018-pitchbook-nvca-venture-monitor. Published January 2019. Accessed April 2019. Jacoby R, Pernenkil L, Harutunian S, et al.; Deloitte. Advanced biopharmaceutical manufacturing: an evolution underway. https://www2.deloitte .com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-advanced-biopharmaceutical-manufacturing-white-paper-051515 .pdf. Published 2015. Accessed May 2017. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Industry roadmap for progress on combating antimicrobial resistance. https://www.ifpma.org/resource-centre/industry-roadmap-for-progress-on-combating-antimicrobial-resistance. Published September 20, 2016. Accessed April 2018. Battelle Technology Partnership Practice; for PhRMA. STEM: building a 21st century workforce to develop tomorrow’s new medicines. http:// phrma-docs.phrma.org/sites/default/files/pdf/stem-education-report-2014.pdf. Published January 2014. Accessed May 2017. TEConomy Partners; for PhRMA. Closing the gap: increasing global competition to attract and grow the biopharmaceutical sector. http://phrma -docs.phrma.org/files/dmfile/PhRMA-InternationalReport-vfinal.pdf. Published June 2017. Accessed June 2017. TEConomy Partners; for PhRMA. Enhancing today’s STEM workforce to ensure tomorrow’s new medicines: biopharmaceutical industry partnerships with U.S. colleges and universities. http://phrma-docs.phrma.org/files/dmfile/TEConomy-PhRMA-STEM-Report-Final.pdf. Published June 2017. Accessed June 2017. Battelle Technology Partnership Practice, Pharmaceutical Research and Manufacturers of America (PhRMA). The US biopharmaceutical industry: perspectives on future growth and the factors that will drive it. http://www.phrma.org/sites/default/files/pdf/2014-economic-futures-report.pdf. Accessed May 2017. Lesser N, Terry C, Wu J, et al.; Deloitte. In the face of uncertainty: a challenging future for biopharmaceutical innovation. http://www2.deloitte .com/content/dam/Deloitte/lu/Documents/life-sciences-health-care/us_consulting_Inthefaceofuncertainty_040614.pdf. Published 2014. Accessed May 2017. 153 7 Economic Impact
Slide 158-

Photo placeholder 154
Slide 159-

INTERNATIONAL COSTS AND ACCESS Prescription Medicines in Other Developed Countries Of the new medicines launched globally each year, far more are available in the United States than in other developed countries. As a result, US patients have better outcomes for conditions where new medicines are most critical. Spending on prescription medicines is a similarly small percentage of total health care spending in the United States as in other developed countries. Consequently, medicines account for a small share of the overall difference in per capita health spending between the US and these other countries. US market-based prices for new medicines incentivize the large and uncertain investments required to bring new medicines to market. While the US system makes efficient use of cost saving generics and competition among brand medicines, other wealthy countries use a variety of government mandates or controls to set artificially low prices for new medicines. Emulating those practices in the United States would lead to reduced R&D and innovation, harming patients with unmet medical needs. 8 155 155
Slide 160-

More Medicines Are Available to US Patients New China Zealand Australia France Canada South Korea Japan Italy US Germany UK 198 182 166 156 152 140 109 109 63 88% 41 64% 59% 54% 51% 50% 46% 36% 36% 21% 13% Nearly 90% of newly launched medicines from 2011 to 2018 were available in the United States, compared to just two-thirds in Germany, half in France, and even less in Canada and Australia. Number of New Medicines Available by Country* (of 307 drugs launched 2011-2018) 270 *New Molecular Entities (NMEs) approved by the FDA, European Medicines Agency (EMA), and/or Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and launched in any country between 2011 and 2018. For example, of the 16 new diabetes medicines launched over the period, only three were available in France. 156 8 International Costs and Access Source: PhRMA analysis of IQVIA Analytics Link and FDA, EMA, and PMDA data1
Slide 161-

US Patients Have Significantly Greater Access to New Cancer Medicines Other developed countries use centralized government price setting and coverage decisions to manage drug spending. As a result, patients in those countries have fewer cancer medicines available to them than US patients. International Approval and Coverage Decisions of 45 Oncology Drugs Approved in the US and Covered by Medicare, 2009-2013 Canada Australia United Kingdom France Approved and Covered Approved and Not Covered Not Approved 157 8 International Costs and Access Source: Zhang Y et al.2
Slide 162-

US Patients Have Access to Cancer Medicines on Average 2 Years Earlier 0 5 10 15 20 25 30 35 Months To the extent that patients in other developed countries have access to cancer medicines, they have to wait longer to access those medicines compared to patients in the United States. Average Delays in Oncology Medicine Approval and Reimbursement in Other Countries Following US Approval, 2010-2014 Delay in Drug Approval Delay in Coverage and Reimbursement 158 8 International Costs and Access Source: IMS Consulting Group3
Slide 163-

US Patients Have Better Outcomes for Conditions Where New Drugs Are Most Critical *2013 is the latest year for which data are available for all listed countries. 100 105 110 115 120 UK Germany France Italy US 122.8 119.7 115.2 Cancer death rates are lower in the United States, where patients have greater and more timely access to cancer medicines than in other developed countries. Age-Standardized Cancer Death Rates, 2013* 130 128.9 125 120.5 Deaths per 100,000 159 8 International Costs and Access Source: PhRMA analysis of WHO data4
Slide 164-

Lung Cancer Patients Experience Better Survival Under the Market Access Policies in the United States American patients diagnosed with locally advanced and metastatic non-small cell lung cancer (NSCLC) gained an estimated 201,700 life-years in total due to innovative medicines being made available with little to no delay after regulatory approval. Half of these survival gains would have been lost if the United States had adopted health technology assessment frameworks like those used by foreign governments to determine access to care. Estimated Share of US Survival Gains Lost if the United States Had Adopted Foreign Government Access Policies for NSCLC Medicines* -80% -70% -60% -50% -40% -30% -20% -10% 0% Korean Access Policies United Kingdom Access Policies Canadian Access Policies Australian Access Policies -54% -74% French Access Policies -13% -52% -54% Percentage of US Survival Gains Lost *US NSCLC patients diagnosed between 2006 and 2017 160 8 International Costs and Access Source: IHS Markit5
Slide 165-

Use of Generic Medicines Is Highest in the United States Payers in the United States drive rapid and widespread adoption of generic medicines, allowing them to devote more resources toward covering and reimbursing innovative medicines than payers in other developed countries. Generic Share of Total Prescriptions Filled, 2017 US Germany New Zealand Canada UK South Korea France Australia Japan Italy 66% 64% 60% 71% 74% 79% 78% 81% 86% 53% 161 8 International Costs and Access Source: PhRMA analysis of IQVIA MIDAS® data6
Slide 166-

Spending on Prescription Medicines Is a Small Percentage of Total Health Care Spending Around the World 14% United States 13% Germany 16% Japan 16% South Korea 10% Australia 15% Italy 12% Spain 11% United Kingdom Prescription Medicines as a Percentage of Total Health Care Spending,* 2015 14% Canada 13% France *Total health care spending includes hospital care, physician and clinical services, home health and nursing home care, government administration and net cost of private health insurance, dental and other professional services, as well as durable medical equipment. Source: Altarum Institute7 162 8 International Costs and Access
Slide 167-

Medicines Account for a Small Share of Health Spending Differences Between the United States and Other Countries Per Capita Health Care Spending in the United States, Canada, and Germany, 2017 $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 $8,000 $10,000 $9,000 $11,000 Germany Canada United States $10,209 All Other Health Care $4,826 Rx Medicines $5,729 All Other Health Care Rx Medicines All Other Health Care Rx Medicines Other health care services, such as hospitalizations and physician visits, drive the large majority of spending differences between OECD* countries. *Organisation for Economic Co-operation and Development 163 8 International Costs and Access Source: PhRMA analysis of OECD data8
Slide 168-

If Governments of Other Wealthy Countries Valued Medicines Fairly, Patients Globally Would Benefit If prices for medicines in other OECD countries were just 20% higher, the resulting increase in R&D would benefit patients around the world, including those in the United States. 164 8 International Costs and Access Sources: Schwartz TT et al.9; USC Schaeffer Center10
Slide 169-

IQVIA Analytics Link. https://www.iqvia.com/solutions/commercialization/market-analysis/analytics-link. Accessed May 2019. Zhang Y, Hueser HC, Hernandez I. Comparing the approval and coverage decisions of new oncology drugs in the United States and other selected countries. J Manag Care Spec Pharm. 2017;23(2):247-254. IMS Consulting Group report for PhRMA. Patient access to innovative oncology medicines across developed markets. June 2016. World Health Organization (WHO). WHO mortality database. http://www.who.int/healthinfo/mortality_data/en. Accessed May 2019. PhRMA analysis of data, using age-specific death rates. Su W, Lockwood C; IHS Markit. Comparing health outcome differences due to drug access: a model in non-small cell lung cancer. https://cdn.ihs .com/www/prot/pdf/0119/IHSM_NSCLC%20HTA%20model%20white%20paper_18Jan2019r.pdf. Published December 13, 2018. Accessed April 2019. IQVIA MIDAS® audited data. April 2019. Altarum Institute; for PhRMA. A ten year projection of the prescription drug share of national health expenditures including non-retail. https:// altarum.org/sites/default/files/uploaded-publication-files/Non-Retail%20Rx%20Forecast%20Data%20Brief%20with%20Addendum%20May %202017.pdf. Published October 2014. Updated May 2017. Accessed June 2018. Organisation for Economic Co-operation and Development (OECD). Health resources. Health spending and pharmaceutical spending indicators. https://www.oecd-ilibrary.org/social-issues-migration-health/health-resources/indicator-group/english_777a9575-en Schwartz TT, Ward AS, Xu XM, et al. The impact of lifting government price controls on global pharmaceutical innovation and population health. Value Health. 2018;21(suppl 1):S119. Goldman D, Lakdawalla D; Leonard D. Schaeffer Center for Health Policy & Economics (USC Schaeffer Center). The global burden of medical innovation. http://healthpolicy.usc.edu/Global_Burden_of_Medical_Innovation.aspx. Published January 2018. Accessed May 2018. Notes and Sources 165 8 International Costs and Access
Slide 170-

166 Photo placeholder
Slide 171-

ppt slide no 171 content not found
Slide 172-

CH A RT PACK goboldly.com TM Pharmaceutical Research and Manufacturers of America 950 F Street NW, Suite 300 | Washington, DC 20004 CONNECT WITH PHRMA: phrma.org facebook.com/PhRMA @PhRMA

User Presentation
Related Presentations

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 1

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 1

DOI System (Digital Object Identifier System): overview

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 5

Value of Pharmaceuticals in Managed Care Pharmacy

EvaluatePharma Orphan Drug Report 2020

Peripheral Vasadilators

Pharmacogenetics and Pharmacogenomics

Value of Personalized Medicine

Pharmacology Manuals

Antidislipidemic Drugs

HEALTH A TO Z